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1. Introduction 
1.1 SPINAL MUSCULAR ATROPHY 
Spinal muscular atrophy as a general term includes many different motor neuron disorders, 
in which proximal muscles and motor neurons are involved. Due to different modes of 
inheritance, there exist several possible forms of spinal muscular atrophies that include 
autosomal dominant and recessive, as well as X-linked ones. Among these are spinal 
muscular atrophy with respiratory distress (SMARD) (Grohmann et al. 2003), spinal and 
bulbar muscular atrophy (Kennedy’s disease), X-linked spinal muscular atrophy (XL-SMA) 
(Baumbach-Reardon et al. 1993) and distal spinal muscular atrophy (Takata et al. 2004). In 
this thesis, spinal muscular atrophy refers to the recessive autosomal type, caused by 
functional loss of SMN1 gene. 
Nowadays, autosomal recessive proximal spinal muscular atrophy (SMA) is the leading 
genetic cause of infant death (Montes et al. 2009). In the Western European population, 
SMA is the second most frequent autosomal recessive disorder in humans after cystic 
fibrosis. The incidence of SMA is 1 in 10,000 live births in Western Europe (Pearn 1978; 
Emery 1991). The carrier frequency is 1:35 – 1:40 (Feldkotter et al. 2002; Wirth et al. 2013). 
Homozygous loss or mutation of the disease-causing Survival of motor neuron gene 1 
(SMN1) located on chromosome 5q13 (Brzustowicz et al. 1990; Melki et al. 1990) leads to 
SMA. This results in the degeneration of spinal α-motor neurons as well as their respective 
efferent axons. As a consequence, affected individuals suffer from progressive weakness of 
muscles. 
1.1.1 Symptoms 
SMA is caused by the progressive degeneration of α-motor neurons in the anterior horns of 
the spinal cord. This leads to a steadily increasing hypotonia and weakness of the voluntary 
muscles, e.g. limb or intercostal muscle of the chest and ultimately resulting in the atrophy 
of proximal voluntary muscles. Although diaphragmatic strength is usually intact, weakening 
of intercostal chest muscles can lead to a severely restrictive lung deficit and finally to the 
need of ventilatory support (Markowitz et al. 2004). While the atrophy is more pronounced 
in the lower extremities, hands and feet are usually spared in the early stages of SMA 
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(Markowitz et al. 2004). Later symptoms, especially in the less affected type II, III or IV 
patients (1.1.2), typically also include progressive weakening of the distal muscle. Since 
muscles of the legs are affected first, patients will usually be wheelchair bound or suffer 
major problems in climbing stairs or getting up from the floor. With ongoing progression and 
depending on the severity of the disease, further symptoms include a weak cough, 
difficulties to suck and swallow, bladder weakness, tremor of the hands, areflexia and an 
increased susceptibility to respiratory tract infections (Rudnik-Schöneborn et al. 1994). In 
contrast, facial and oculomotor nerves are typically unaffected and also cognitive skills are 
not impaired. The denervation of muscle finally results in atrophy, whereby often a few 
residual motor neurons stay connected. The uncontrolled and sporadic firing of such 
remaining motor neurons leads to twitching (fasciculation), particular of the tongue and 
fingers, a finding often used in diagnosis (Markowitz et al. 2004). 
1.1.2 Classification 
Phenotypical variation of SMA, ranging from very severe forms with early onset to rather 
mild chronic SMA disease, led to the development of a classification scheme for SMA. The 
characteristics of five types (SMA type 0-IV) will briefly be outlined as defined by the 
International SMA Consortium in 1992 (Munsat and Davies 1992). Classification criteria that 
are relevant to the clinic were used to define types of SMA, among these are age of onset 
and distribution of muscle weakness (Russman 2007; Wang et al. 2007). Type 0 SMA is 
considered the most severe form of SMA with perinatal onset, problems to swallow and 
breath, possible facial dysplasia and no motoric abilities (Russman 2007). Type I SMA 
(Werdnig-Hoffmann disease), also called the infantile acute form of SMA, accounts for ~60% 
of all SMA cases (Werdnig 1891; Pearn 1978; Markowitz et al. 2004; Monani and De Vivo 
2014). The onset of disease is before the age of 6 months with a life expectancy of less than 
two years (Rudnik-Schoneborn et al. 2009). The proportion of patients surviving more than 
2 years is ~6% (Rudnik-Schoneborn et al. 2009; Cobben and de Visser 2002; Carre and 
Empey 2016). Patients will never be able to sit or walk independently. Proximal intercostal 
muscles are strongly affected and patients suffer from severe breathing problems 
concomitant with an increased infection rate. Many patients undergo gastrostomy for 
swallowing problems and are not able to thrive properly, or are in need of a non-invasive 
ventilation and tracheostomy due to their respiratory difficulties (De Sanctis et al. 2016). The 
onset of type II SMA (intermediate form) is between 6 and 18 months. Patients are mostly 
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able to sit but cannot walk. The prognosis is rather variable depending on the degree of 
respiratory muscle involvement and the problems associated with the development of 
kyphoscoliosis (Talbot 1999). Type III SMA or juvenile SMA (Kugelberg and Welander 1956) 
is quite variable in its age of onset but generally first symptoms occur after the 18th month 
of life. Depending on the exact age of onset, SMA type III is divided into two subtypes: if first 
symptoms are diagnosed before the age of three years, the disease is called type IIIa, if the 
patient is older than three years it is called type IIIb (Zerres and Rudnik-Schoneborn 1995). 
Type III SMA is very heterogeneous, as some affected individuals may need wheelchair 
assistance in childhood, whereas others may continue to walk throughout their whole lives. 
SMA Type IV (adult form) is a very mild form of SMA with a rather late onset beyond the age 
of 30 (Zerres and Rudnik-Schoneborn 1995). As in all SMA forms, weakness is progressive 
but affects mostly proximal muscles. Type IV patients have a normal life expectancy. 
1.1.3 SMN1 and SMN2 genes 
In 1995, the survival of motor neuron 1 gene (SMN1) was identified as the SMA-determining 
gene (Lefebvre et al. 1995), while SMN2, a paralog of SMN1, is the major modifier of SMA 
disease severity (Feldkotter et al. 2002). Each SMN gene copy lies within a repeat unit of a 
copy number variant (CNV) on chromosome 5q13, while each repeat unit is about 500 kb 
and oriented in inverse direction (Lefebvre et al. 1995; Burglen et al. 1996). The SMN1 gene 
encompasses a 28 kb genomic region and comprises 10 exons (1, 2a, 2b, 3, 4, 5, 6a, 6b, 7 
and 8). The coding sequence of SMN1 is 882 bp and produces a ~1.5 kb transcript, which 
is ubiquitously expressed (Lefebvre et al. 1995; Chen et al. 1998) and encodes for a protein 
of 294 amino acids. SMN1 was found to be highly conserved between species (Miguel-
Aliaga et al. 1999; Paushkin et al. 2000), emphasizing that it is essential for every organism. 
SMN2 differs from SMN1 by only five nucleotide exchanges localized at the 3’end of the 
genes: one nucleotide exchange in each of the exons 7 and 8 and intron 6 and two in intron 
7 (Lefebvre et al. 1995; Burglen et al. 1996). Besides SMN, another four genes have been 
shown to be included in the duplicated 500 kb segment: BIRC1 (baculoviral IAP repeat-
containing protein 1) which is also known as NAIP (neuronal apoptosis inhibitory protein), 
SERF1 (small EDRK-rich factor 1), also termed H4F5, GTF2H2 (general transcription factor 
IIH) or p44 (Figure 1), and OCLN (occludin) (Lefebvre et al. 1995; Schmutz et al. 2004). 
Proximally, this highly polymorphic region is flanked by RAD17, whereas the distally 
adjacent gene is BDP1 (Deimling von et al. 1999; Kelter et al. 2000). 
4 Introduction 
 
 
 
Figure 1: 500 kb telomeric and centromeric region containing SMN1 and its duplicated version SMN2, 
respectively. In the centromeric region, a nearly identical copy of SMN1 is located, termed SMN2, which has 
been found to be present in all SMA patients. SMN2 differs from SMN1 by only 5 silent discrepancies: a 
synonymous mutation in exon 7 (c.C280T in SMN2), exon 8 (nt 27869 G>A), intron 6 (nt 27092 G>A) and 
another two in Intron 7 (nt 27289 A>G and 27404 A>G) (Lefebvre et al. 1995; Burglen et al. 1996). 
All other variants are not specific to either of the two copies. The c.C280T transition in exon 
7 of SMN2 is translationally silent but causes the disruption of an exonic splicing enhancer 
(ESE) (Lorson et al. 1999; Cartegni and Krainer 2002) and additionally creates a new 
splicing silencer (Kashima and Manley 2003). 
 
Figure 2: Pre-mRNA splicing of SMN1 and SMN2. In SMN1, an exonic splicing enhancer (ESE) which 
contains the nucleotide cytosine (C) at position six in exon seven (Ex7+6), is recognized by splicing factor 2 
or alternative splicing factor (SF2/ASF) which interacts (thick black arrow) with the U2 class of small nuclear 
ribonuclear protein (U2 snRNP) to remove intron six. Other splicing factors (e.g. SFRS10) determine splicing 
through interactions (thin black arrow) with ESE elements found centrally within exon seven. Serine and 
arginine (SR)-rich proteins might also exert a positive splicing effect. In SMN2, the ribonucleotide uridine 
(transcribed from thymidine) at Ex7+6 favours exon seven exclusion by binding to heterogeneous nuclear 
ribonuclear protein (hnRNP) A1; a negative splicing factor. Moreover, SF2/ASF no longer recognizes this 
sequence motif. Binding of hnRNP A1 is also believed to prohibit U2 snRNP binding to the branch point which 
results in about 90% of SMN2 final mRNA transcripts with no exon seven. The positive splicing factors 
downstream (thin black arrow) are functioning and could account for exon 7 inclusion in about 10% of SMN2 
transcripts. (taken from (Lunn and Wang 2008)) 
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As a consequence, 90% of SMN2 pre-mRNAs are alternatively spliced lacking exon 7. Only 
about 10% of SMN2 mRNA transcripts are correctly spliced and encode a protein identical 
to that generated by the SMN1 gene. Exon 7 skipping leads to a frameshift and an alternative 
stop codon in exon 8 (Figure 2), encoding for a truncated protein (Δ7SMN2) of reduced 
oligomerization capacity and stability (Lorson et al. 1998; Lorson and Androphy 2000). The 
truncation generates a degradation signal at the C-terminal part of the SMN protein, which 
leads to rapid degradation by the proteasome pathway (Cho and Dreyfuss 2010). A large 
genetic variability has been found concerning the number of repeat units (null to four) per 
chromosome, the size and orientation of this CNV, which can lead to rearrangements and 
SMN2 copy numbers being variable among the population. Although a strong inverse 
correlation has been found between the number of SMN2 copies and disease severity 
(Feldkotter et al. 2002), this correlation is not absolute, as the genetic integrity, splicing, 
transcription, translation and stability of the SMN2 gene, RNA or protein can be influenced 
by various cis or trans or even exogenous factors (Wirth et al. 2013). In general, the more 
SMN2 copies a patient has, the milder the phenotype. Most SMA type I patients carry two 
SMN2 copies, SMA type II patients carry three SMN2 copies, SMA type III patients carry 
three or four copies and SMA type IV usually carry up to six SMN2 copies (Feldkotter et al. 
2002; Wirth et al. 2006). The correlation between copy number of SMN2 and the severity of 
the SMA phenotype in mouse and human is depicted in Figure 3. Noteworthy, there are the 
different requirements of FL-SMN2 levels in humans and mice to fully compensate for the 
lack of SMN1 and Smn, respectively. It has been shown that three copies of SMN2 are 
enough to rescue the survival in the SMA mouse model, while in humans 6-8 SMN2 copies 
compensate for the lack of SMN1 gene (Michaud et al. 2010; Wirth et al. 2013). Interestingly, 
cases have been reported, in which patients develop a mild type III SMA despite having only 
2 SMN2 copies and vice versa, type I SMA patients have been identified carrying 3 SMN2 
copies (Feldkotter et al. 2002). They hypothesized that these unexpected correlation 
between SMN2 copy numbers and phenotypic appearance might be due to modifying genes 
or other external factors, intragenic mutations within SMN2, or SMN2 genes being partially 
deleted or duplicated. SMN2 occurred during a recent evolutionary event during transition 
from primates to humans. The gene duplication event occurred for the first time in primates 
roughly five million years ago. However, also in man’s closest relative Pan troglodytes, only 
two to seven copies of SMN1 are present whereas the SMN2 gene is unique to humans 
(Rochette et al. 2001) Since homozygous mutations in any species carrying a single copy 
cause early embryonic lethality (Schrank et al. 1997), SMN2 and SMA are human-specific. 
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Figure 3: Different requirement of SMN2 gene compensate the SMA phenotype in human and mouse. 
Since each SMN2 produces 10% functional FL-SMN protein, more SMN2 copies lead to a milder phenotype 
or complete rescue (Wirth et al. 2013). Note the different requirement of FL-SMN2 levels in humans and mice 
to fully compensate for the lack of SMN1 and Smn, respectively. In mice three instead of two SMN2 copies 
lead to an almost normal phenotype. In humans only eight copies lead to a normal phenotype. 
1.1.4 SMN protein 
The human SMN protein is a 294 aa protein of about 38 kDa in size and ubiquitously 
expressed in all tissues, with highest levels present in the CNS and liver (Carvalho et al. 
1999; Young et al. 2000; Young et al. 2001). Since SMN abundance markedly declines after 
birth, it is thought that elevated SMN levels may play an important role throughout prenatal 
development (Burlet et al. 1998). Inside the cell, SMN is present in both the cytoplasm and 
the nucleus. While in the cytoplasm it is diffusely distributed, distinct SMN foci are observed 
inside the nucleus (Burlet et al. 1998; Coovert et al. 1997; Liu and Dreyfuss 1996). These 
very bright dot-like structures in the nucleus termed gemini of Cajal bodies (CBs), or gems 
are often located in close proximity or overlap with CBs, which play an important role in RNA 
transcription and processing (Young et al. 2001; Schul et al. 1998; Lyon et al. 1997). Like 
the majority of cytoplasmic proteins, SMN is degraded via the ubiquitin-proteasome-system 
(UPS) (Burnett et al. 2009; Chang et al. 2004). The SMN protein consists of several 
functional domains. N-terminally, exon 2b and the beginning of exon three encode for an 
RNA-binding-domain (RBD) (Bertrandy et al. 1999), whereas the major part of exon 3 is 
spanned by a Tudor-domain, facilitating Sm protein binding during U snRNP biogenesis 
(Selenko et al. 2001). Exons 4 and 5 carry a proline-rich stretch, facilitating interaction with 
Profilins (Bowerman et al. 2009; Bowerman et al. 2007; Giesemann et al. 1999). In addition, 
the YG-box, encoded by exon 6 in conjunction with exon 2b (Lorson et al. 1998) is required 
for SMN self-oligomerization. 
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1.1.5 SMN function 
Since the SMN protein possesses diverse functions in many different environments and 
subsequently in a plethora of cellular pathways and molecular mechanisms, its functions are 
categorized into a) housekeeping functions, b) neuron specific functions and c) muscle 
specific functions and briefly outlined in the following: 
1.1.5.1 Housekeeping functions 
Biogenesis of snRNPs 
Small nuclear ribonucleoproteins (snRNPs) are actively participating within the splicing 
machinery of every cell. The role of the snRNPs is to recognize and remove introns from 
pre-mRNAs structures (Pellizzoni 2007). Members of the hnRNP family consists of small 
nuclear RNAs called U1 U2, U4 and U5, U11 and U12 and a protein part. The latter is made 
of a number of specific proteins that are unique for each snRNP and form a heptameric ring 
of Sm (Smith antigen) proteins (B/B', D1, D2, D3, E, F, and G) (Liu et al. 1997). This Sm ring 
is important for snRNP stability and function as well as for nuclear localization of snRNPs. 
The SMN complex facilitates addition of the Sm proteins onto the respective snRNA and 
catalyzes Sm ring closing (Lorson et al. 1998; Meister and Fischer 2002; Pellizzoni et al. 
1999). SMN, GEMIN2–8 and UNR-interacting protein (UNRIP) together form the SMN 
complex (Gupta et al. 2015). The SMN protein unfolds its proper function only as an oligomer 
(Lorson et al. 1998; Pellizzoni et al. 1999). It has been shown to form higher-order 
complexes ranging from 20S to 80S. Several point mutations in SMN1 have been shown to 
impair binding of SMN to the Sm proteins, thus leading to generalized splicing defects 
(Gabanella et al. 2007; Lorson et al. 1998; Pellizzoni 2007; Sun et al. 2005; Zhang et al. 
2008). 
Stress response 
Exposure to stress factors such as heat, chemical compounds or UV irradiation activates a 
protective cellular process called stress response. While specific stress-induced genes e.g. 
the heat-shock-proteins (HSPs) are activated in response to stress, most other genes are 
silenced. During cell stress, mRNA transcripts are recruited and dynamically sorted into 
cytosolic compartments forming so called stress granules (SG) to protect mRNA transcripts 
from degradation or denaturation (Kedersha and Anderson 2009). SGs have been proven 
to serve as transient local storage compartment for mRNAs and only while recovering from 
stress exposure, SGs reassemble and mRNA transcripts are again available for further 
translation (Nover et al. 1989). Stress granules are formed by shuttling the RNA binding 
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proteins TIA-1(T-cell internal antigen-1) and TIA-R (TIA1-related protein) from the nucleus 
into the cytoplasm where these proteins self-aggregate and colocalize with poly (A) 
containing mRNA (Kedersha et al. 1999). However, it has been observed that SMN protein 
co-localizes and interacts with TIA-1 and TIAR, which accumulate in stress granules (Hua 
and Zhou 2004a, b). This finding suggests that SMN contributes to formation and function 
of SGs. 
1.1.5.2 Neuron-specific functions 
The modifying factor PLS3 positively influences axonal integrity and nerve connectivity in 
SMA mice at the level of the neuromuscular junction (Ackermann et al. 2013). Therefore, 
the particular focus of this chapter is on the function of SMN in axonal mRNA transport and 
translation, axonal growth, as well as NMJ maturation. 
Axonal mRNA transport and translation 
In the past, several different findings led to the assumption that SMN is involved in RNA 
transport along axons, as well as translational regulation. FMRP (Fragile mental retardation 
syndrome protein), which is crucial for mRNA transport and translation, was found to be a 
direct interactor of the SMN protein (Piazzon et al. 2008). Additionally, SMN granules that 
colocalize with RNAs were actively transported to the growth cones, indicating an 
involvement of SMN in axonal transport of mRNA and mRNA binding proteins (Zhang et al. 
2003). Moreover, a reduction of ß-Actin mRNA at the growth cones of MNs derived from 
SMA mice and SMN-depleted PC12 cells, has been reported, additionally suggesting an 
involvement of SMN in mRNA transport along axons (Rossoll et al. 2003). hnRNP R, which 
controls ß-Actin localization (Rossoll et al. 2003) and directly interacts with the SMN protein, 
was found to be present at the presynapse of NMJs of pre- or neonatal mice, supporting a 
contribution of SMN beyond snRNP assembly (Dombert et al. 2014). Through live cell 
imaging it has been demonstrated that SMN granules traffic bidirectionally along neuronal 
compartments and to the growth cones of MNs (Zhang et al. 2006; Zhang et al. 2003). Taken 
together, these finding suggest that SMN is actively involved in recruitment and transport of 
axonal mRNAs along the axons and eventually to the axon terminals. 
In the past it has already been discussed that SMN may have a specific function in regulating 
translation in neurons (Piazzon et al. 2008; Bardoni et al. 2001). Very recently it has been 
reported that in MNs derived from SMA mice SMN deficiency severely disrupts local protein 
synthesis within neuronal growth cones. These mice show reduced levels of cytoskeleton-
associated growth-associated protein 43 (GAP43) mRNA and protein in axons and growth 
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cones. Most importantly, HuD and IMP1 overexpression, which are mRNA-binding proteins, 
restores GAP43 mRNA and protein levels in growth cones and rescues axon outgrowth 
defects in SMA neurons. These findings furthermore emphasize that SMN is an important 
player in the localization and local translation of mRNAs with important axonal functions 
(Fallini et al. 2016). 
Neurite outgrowth 
In previous studies, a novel, shorter isoform of SMN called aSMN (axonal SMN) has been 
identified, which was only found in axons of MNs. There it was found to trigger axonogenesis 
(Setola et al. 2007). Furthermore, SMN overexpression has been shown to induce neurite 
outgrowth and could rescue SMN knock-down effects in zebrafish and mice (Bowerman et 
al. 2009; Fan and Simard 2002; McWhorter et al. 2003; Oprea et al. 2008). Neurite outgrowth 
as well as neurite branching are both actin-dependent processes (Schmidt and Rathjen 
2010). Reduction of the endogenous SMN altered the G-/F-actin ratio significantly, which 
further indicated SMN involvement in actin dynamics and microfilament metabolism in MN 
axons (van Bergeijk et al. 2007). The protective modifier PLS3 is an actin-bundling protein 
restoring disturbed G-/F-actin ratios in SMA patients (Oprea et al. 2008), as well as SMA 
mice (Ackermann et al. 2013). Therefore, the influence of actin on the MN integrity will be 
discussed in more detail in chapter 1.2.2. Furthermore, in zebrafish experiments the knock-
down of Smn led to an earlier branching of axons, underlining the important role of Smn in 
motor axon-specific pathfinding and motor axon development (McWhorter et al. 2003). 
Neuromuscular junction formation and maintenance (NMJ) 
In fly, Drosophila melanogaster, developmental and motor behaviour deficits were observed 
due to reduced endplate currents and endplate disorganization (Chan et al. 2003). These 
findings led to the assumption of primary defects at the neuromuscular junction (NMJ) in 
SMA. NMJs are the connecting pieces between the axon terminal of a MN and the respective 
muscle. Histological inspection of SMA mice revealed that the maturation of NMJs was 
severely reduced and AChR (Acetylcholine Receptor) clusters did not form proper pretzel-
like structures. Moreover, pre-terminal sprouting was also decreased (Kariya et al. 2008). 
Electrophysiological examinations showed that reduced SMN levels in mice indeed led to 
lower evoked endplate currents (EPC) due to reduced neurotransmitter release (Kong et al. 
2009). Also in the vertebrate Xenopus laevis, motor neuron abnormalities with reduced 
axonal outgrowth and abnormal formation of branching extensions have been described 
(Ymlahi-Ouazzani et al. 2010). Severe SMA mice exhibit a significant reduction of axonal 
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inputs per endplate during synapse elimination process, also termed axonal pruning 
(Ackermann et al. 2013), in proximal TVA muscle (Murray et al. 2008). In addition, 
electrophysiological recordings of synaptic activity at the NMJ have shown a number of 
abnormalities in Smn depleted mice (Torres-Benito et al. 2011). Furthermore, also the 
distribution of vesicles in the presynapse appeared abnormal in SMA animals (Kariya et al. 
2008). The functional defects observed in NMJs of SMA mice manifest also in altered 
morphological appearance of both pre- and postsynaptic structures. SMA presynapses 
occur with NF accumulations that participate in MN dysfunction, e.g. by slowing down the 
transport of components required for axonal and synaptic maturation and maintenance 
(Kariya et al. 2008; Kong et al. 2009; Ruiz et al. 2010; Torres-Benito et al. 2011). The defects 
observed at SMA postsynapses affect mainly the maturation process of Acetyl Choline 
receptor (AChR) clustering. While in wt oval AChR plaques are transformed into complex 
adult synapses with a so-called pretzel-like structure, SMA animals display small and still 
oval shaped endplates with almost no gutters of perforations and postsynaptic membrane 
folds fail to form (Torres-Benito et al. 2011; Sanes and Lichtman 1999). The NMJ pathology 
rather than axonal defects leads to characteristic disease features in SMA mice (Ackermann 
et al. 2013). 
1.1.5.3 Peripheral organ-specific functions 
Although SMA is primarily considered a neuromuscular disease mainly affecting the 
neuronal circuitry with NMJ pathology and loss of α-motor neurons, and only secondarily 
leading to muscles atrophy, a muscle specific role of SMN has also been discussed 
previously. After knock-down of Smn in C2C12 myoblast, severe defects in myoblast fusion 
and abnormal myotube morphology have been reported (Shafey et al. 2005). These defects 
are most likely due to Z-disc deficiency, as the entire SMN protein complex is localized to 
the sarcomeric Z-disc and SMN is a direct target of calpain-3-mediated proteolytic cleavage 
(Walker et al. 2008; Shafey et al. 2005). 
Previous studies revealed that in absence of neuronal SMN, the muscle specific 
overexpression is not sufficient to improve the SMA phenotype in several SMA animal 
models. In contrary to that, neuron specific SMN expression alone significantly increased 
survival but did not completely rescue the SMA phenotype (Chan et al. 2003; Gavrilina et 
al. 2008). Therefore, the hypothesis that SMA might be caused by a muscle specific 
reduction of SMN was repelled. 
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As described in more detail in the following chapter, severely affected SMA mice die early 
as they do not only show defects within the neuronal circuitry and the affected muscle but 
also suffer from inner organ impairments such as heart, lung, liver and intestine (Schreml et 
al. 2013; Riessland et al. 2010; Shababi et al. 2014; Hayhurst et al. 2012; Shababi et al. 
2012; Bevan et al. 2010; Heier et al. 2010; Butchbach et al. 2010; Bowerman et al. 2012b; 
Cifuentes-Diaz et al. 2001; Hua et al. 2011; Vitte et al. 2004). In consideration of our present 
work the so-called threshold theory may be of great importance. It suggests different 
susceptibility of certain cells to SMN depletion. When SMN amounts are only marginally 
reduced, MNs are already affected. As SMN levels further decrease or even completely 
vanish (Sleigh et al. 2011), heart, lung, liver, intestine and all other tissue types get affected 
eventually. 
1.1.6 SMA mouse models 
To investigate the pathomechanisms of SMA, many different SMA mouse models have been 
generated over the last two decades. In contrast to humans, where a second copy of SMN1 
is present, the SMN1 orthologue in mouse, Smn, has been shown to exist as a single copy 
gene (DiDonato et al. 1999; DiDonato et al. 1997; Viollet et al. 1997). The homozygous 
knockout of Smn is embryonically lethal, indicating that Smn is indispensable throughout all 
cell types (Schrank et al. 1997; Hsieh-Li et al. 2000; Park et al. 2010). In the following, a 
variety of SMA mouse models will be presented. In 1997, the first classical knock-out of the 
murine Smn gene was described. The researches disrupted exons 2 - 4 of the Smn gene 
and reported an early embryonic lethality before implantation between day E2.5 and E3.5 
(Schrank et al. 1997). In 2000, another group genetically replaced a 1.6 kb fragment of the 
Smn gene including exon 7 with a HPRT (hypoxanthine phosphoribosyl transferase) 
cassette and observed normally developing embryos at E3.5 but not at E6.5, indicating an 
essential role of Smn in the embryonic development (Hsieh-Li et al. 2000). Heterozygous 
SmnKO/wt mice showed no symptomatic muscle atrophy, but a ~50% reduction of the SMN 
protein level and a resulting degeneration of the α-motor neurons after 6 months of life 
(Jablonka et al. 2000). Due to the early embryonic lethality of homozygous knock-out mice, 
however, this SMA model was not useful to adequately study SMA pathomechanisms. For 
this reason and to more accurately mimic the human situation, the aberrantly spliced human 
SMN2 (hSMN2) gene was introduced into the SmnKO/KO background as a genomic fragment 
(Hsieh-Li et al. 2000; Monani et al. 2000b; Park et al. 2010). 
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1.1.6.1 ‚Monani’ SMA mouse model 
Remarkedly, already one or two copies of the SMN2 transgene are sufficient to overcome 
the early embryonic lethality reported earlier. ‚Monani’ SMA mice carry one copy of hSMN2 
per transgenic allele. Homozygous SmnKO/KO;hSMN2tg/tg mice (two hSMN2 copies) are 
viable but develop severe symptoms including MN loss and motoric disability on P2 and die 
on P4 (Monani et al. 2000b). MNs were dramatically reduced during these first postnatal 
days and SMA animals dying so early resembled more or less a SMA type I. Similarly to 
humans, addition of more SMN2 copies ameliorated the phenotype and eight SMN2 copies 
resulted in a total rescue of these SMA mice, providing the first proof-of-concept study of 
the feasibility of modulating the SMN2 gene for therapeutic purposes (Monani et al. 2000b; 
Park et al. 2010). Heterozygous SmnKO/KO;hSMN2tg/0 with a total of 1 hSMN2 copy, however, 
are embryonically lethal. In addition, a mouse model resembling a milder form of SMA (SMA 
type III) is based on the already mentioned ‚Monani’ SMA mouse model. A transgene 
carrying a missense (A2G) mutation in exon 1 of the SMN gene was introduced into the 
severe SMA genetic background. SmnKO/KO;SMN2tg/tg;SMNA2Gtg/0 mice exhibited many of 
the clinical and pathological characteristics of type III (mild) SMA (Monani et al. 2003). These 
mice suffer from MN degeneration, loss and sprouting, muscle atrophy, and abnormal EMG 
patterns. 
1.1.6.2 Δ7 SMA mouse model 
The most commonly used SMA model today is the so called SMNΔ7-mouse (Le et al. 2005). 
This line carries the Monani-hSMN2 transgene (1 hSMN2 copy per allele) and additionally 
Δ7hSMN2 (an SMN cDNA lacking exon 7), each homozygously, on the Smn null 
background. In SmnKO/KO;hSMN2tg/tg;Δ7hSMN2tg/tg mice a modest attenuation of the SMA 
phenotype was observed with a mean survival of 13.3 ± 0.3 days, demonstrating that also 
Δ7SMN2 is at least partially functional and does not, as was previously alleged, act 
deleterious through dominant-negative effects (Kerr et al. 2000; Le et al. 2005). This was an 
in vivo proof that the SMNΔ7-protein has the capability to associate with the SMN-protein 
and to stabilize the whole SMN-complex and that SMNΔ7 has no detrimental effect on the 
SMA animals (Le et al. 2005). Nonetheless, Δ7 SMA MNs show reduced proprioceptive 
reflexes that correlate with decreased number and function of synapses on MN somata and 
proximal dendrites (Mentis et al. 2011). Although the circuit and synaptic abnormalities that 
contribute to neurodegenerative diseases are complex, previous studies using the Δ7 SMA 
mouse model led to the following hypothesis: As primary afferents and motor neurons both 
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express SMN, it is possible that the phenotypes of sensory and motor neurons in SMA mice 
simply reflect cell-autonomous outcomes of SMN reduction (Mentis et al. 2011). 
Furthermore, the severe denervation in a series of head and trunk muscles in SMNΔ7 mice 
might compromise vital motor functions, which are clinically relevant to SMA patients (Ling 
et al. 2012). 
1.1.6.3 Taiwanese SMA mouse model 
In 2000, Hsieh-Li et al. generated another SMA mouse model, also termed Hung mice or 
Taiwanese SMA mice, by crossing an integrate of a BAC clone carrying 2 hSMN2 copies 
onto the SmnKO/KO background. Several different founder lines were generated on a mixed 
background, exhibiting either a SMA type I, II or III phenotype. Heterozygous 
SmnKO/KO;hSMN2tg/0 animals (2 hSMN2 copies) show a background-dependent survival of 
~10 (FVB/N, (Riessland et al. 2010)) to ~14 d (C57BL/6N, (Ackermann et al. 2013)) while 
homozygous mice of the genotype SmnKO/KO;hSMN2tg/tg (4 hSMN2 copies) are fully viable 
and fertile but show necrosis of ears and tail. Previous studies revealed that the 
heterozygous SmnKO/KO;hSMN2tg/0 animals (from here on called SMA mice) show a cardiac 
phenotype as well as dark red discolorations of the lungs compatible with atelectasis or 
pulmonary infarctions and the intestine appeared empty and string-like and opaque fluid was 
found in the abdomen of most late-stage SMA animals with histological changes in the small 
intestine consisted of reduced numbers of villi (Schreml et al. 2013). Some of the SMA mice 
showed so massive inner organ failure and therefore died unexpectedly early while 
apparently otherwise being in relatively good health and showing little or no motor deficits 
(Schreml et al. 2013). The Hung mouse model offers the big advantage of producing 50% 
of SMA and 50% of control mice within one litter. Since the Hung mouse model was used in 
this study to analyze the effect of PLS3 overexpression on the intermediate SMA phenotype, 
this model including the breeding scheme for the production of SMA mice is described in 
chapter 4.1.2. 
1.1.6.4 Smn2B/KO SMA mouse model 
Furthermore, Smn exon 7 contains a critical AG-rich exonic splice enhancer sequence 
(ESE) analogous to the human ESE within SMN exon 7, and subtle mutations within the 
mESE caused a variation in Smn transcript levels. Specific mutations at the endogenous 
Smn locus lay the foundation for developing SMA animals that closely 'resemble' SMA 
patients (DiDonato et al. 2001). The Smn2B/KO mouse line, obtains a 3 bp substitution in the 
exon 7 exonic splicing enhancer (ESE) (Bowerman et al. 2009). With about 15% normal 
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level of SMN protein, Smn2B/KO mice display significant reduction in body weight, 
abnormalities in locomotion and gait, and a significant reduction in the number of MN cell 
bodies and axonal loss. These mice are phenotype-free until P10 with a median life 
expectancy of 28 days. They show neuromuscular junction (NMJ) pathology with an inter-
muscular differential vulnerability and an association between pre- and post-synaptic 
defects (Bowerman et al. 2012a). The Smn2B/KO mice also display the SMA pathological 
hallmark of motor neuron loss in the brain stem and ventral horn region of the lumbar spinal 
cord (L1–L2). Smn2B/2B mice are phenotypically normal (Bowerman et al. 2012a). 
1.1.6.5 Burgheron mouse model of SMA type II/III 
In 2015, an intermediate SMA mouse model was generated that, in contrast to the 
intermediate Smn2B/KO SMA mouse model, contains the human SMN2 transgene (Bogdanik 
et al. 2015). The mutants are compound heterozygous for the Smn1tm1/Msd knockout of Smn 
(Schrank et al. 1997) and the Smn1tm5 allele (C-allele, made by Regeneron 
Pharmaceuticals) and carry a single copy of the human SMN289Ahmb transgene. This SMN2 
transgene consists of a 35.5-kb BamHI genomic fragment encoding the human SMN2 
promoter and gene (Monani et al. 2000b). The C-allele is a hybrid gene that contains a 
replacement of exon 7 and 8 from the mouse Smn locus by exons 7 and 8 of the human 
SMN2 gene (1.3-kb fragment), and a full 42-kb copy of the human SMN2 gene. The 
Burgheron mutants have a mean survival of 89 days and present with a cardiac phenotype 
as well as tail, limb and ear necrosis. They show a delay in the structural maturation of the 
NMJ. In most severe SMA models and type I and II SMA patients, peripheral axon loss has 
been observed, whereas in Burgheron mutants denervation and abnormal accumulation of 
neurofilament proteins in the nerve terminals did not occur. 
1.1.7 Therapeutic strategies in SMA treatment 
In the past, a lot of effort has been done to develop different therapy strategies to target 
SMA. Although a lot of knowledge has been gained through developing promising drug 
candidates, there is still no cure available for SMA. Since still around 10% of FL-SMN 
transcript are produced by SMN2, compounds, which target its transcription, seem to be 
promising drug candidates. Histone deacetylase inhibitors (HDACi) block the activity of 
histone deacetylases (HDAC) as they shift their modification to the acetylated state and 
thereby activating gene transcription. In SMA mouse models or cell culture experiments, 
HDACi such as Sodium butyrate, valproic acid (VPA), phenylbutyrate, Trichostatin A, 
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suberoylanilide hydroxamic acid (SAHA), M344 and LBH589 had been successfully tested 
to stimulate the SMN2 transcription (Chang et al. 2001; Brichta et al. 2003; Sumner et al. 
2003; Andreassi et al. 2004; Brahe et al. 2005; Brichta et al. 2006; Riessland et al. 2006; 
Avila et al. 2007; Tsai et al. 2008; Garbes et al. 2009; Hauke et al. 2009). 
Additionally, instead of activating gene transcription another idea to increase SMN levels in 
SMA patients might be to stabilize remaining FL-SMN protein. Previous studies revealed 
that SMN is degraded via the ubiquitin/proteasome pathway (Chang et al. 2004; Garbes et 
al. 2009). Therefore, proteasome inhibitors might be an additional promising strategy to treat 
SMA. When tested in cell culture experiments, the proteasome inhibitor MG132 led to an 
increase in SMN protein. 
Moreover, when neural stem cells had been transplanted into the spinal cord of Δ7 SMN 
mice, they differentiated not only into MN-like cells but also protected host MNs from 
degeneration. This stem cell therapy significantly increased survival and improved motoric 
abilities of these animals (Corti et al. 2010). Hence, stem cell therapy has a promising 
potential as a treatment strategy counteracting SMA pathology. The greatest challenge of 
this treatment form is to ensure that transplanted MNs will grow into the respective target 
muscle tissue. Therefore, it is inevitable to use neuroprotective compounds such as brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neurotrophin-4/5 (NT4/5) and 
nerve growth factor (NGF) that are added to the donor cells (Ebert et al. 2009; Wyatt and 
Keirstead 2010; Corti et al. 2010). 
Over the last five years, gene therapy as an additional strategy to target SMA, has been 
tested in mice. In three independent studies, researchers used the self-complementary 
adeno-associated virus 9 (scAAV9) for gene delivery into MNs of SMA mice by intravenous 
injection (Foust et al. 2010; Valori et al. 2010; Dominguez et al. 2011). In 2013, intramuscular 
scAAV9-SMN injection was successfully performed, mediating widespread gene delivery to 
the spinal cord and decreasing disease severity in SMA mice. The survival rate of these 
mice increased from 12 to 163 days (Benkhelifa-Ziyyat et al. 2013). Most strikingly, scAAV9-
SMN was able to cross the blood brain barrier (BBB), highly efficiently transduced MNs in 
the lumbar region of the spinal cord as well as muscle tissue. 
Last but not least, outstanding progress has been achieved in the development of using 
antisense oligonucleotides (ASOs) and morpholinos (Lim and Hertel 2001; Cartegni and 
Krainer 2003; Dickson et al. 2008). This strategy aims at the correction of the SMN2 splicing 
pattern towards increased levels of FL-SMN transcripts. Elevating SMN levels in cell culture 
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and even when ASOs are injected into the brain of SMA mice (Passini et al. 2011; Hua et 
al. 2010; Hosseinibarkooie et al. 2016), delivery into the human CNS remains challenging 
and further clinical trials are indispensable to transfer our gained knowledge from animal 
models to the human SMA patient. As the ASO strategy is used in this study to establish an 
intermediate SMA mouse model some further information about the chemical structure and 
the mode of action of ASOs are highlighted in the following. Figure 4 depicts a variety of 
nucleotide analogues used in ASO drugs (Rigo et al. 2012). 
 
Figure 4: Nucleotide analogues used in antisense oligonucleotide drugs. Antisense oligonucleotides 
(green) bind to the target RNA (purple) by Watson-Crick base pairing (left). Chemical structures of various 
nucleotides or nucleotide analogues commonly used in antisense drugs are shown. The antisense 
oligonucleotide developed by (Rigo et al. 2012) to improve SMN2 splicing has the 2′-MOE modification (red). 
Taken from (Rigo et al. 2012). 
ASOs bind to RNA through Watson-Crick base paring (Figure 4). Once bound to the target 
RNA, there are multiple mechanisms by which antisense-based drugs alter its function, 
including promoting its degradation, interfering with pre-mRNA processing, blocking access 
to the RNA of specific proteins such as RNA-binding proteins and ribosome subunits, and 
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disrupting the secondary and tertiary structure of the RNA (Bennett and Swayze 2010). The 
mechanism by which an ASO elicits these effects is dependent upon the class of RNA, 
where on the RNA the ASO binds, and the chemical composition of the ASO. 
 
Figure 5: Mechanism of action of an antisense drug that modulates SMN2 splicing. Single-stranded 
antisense oligonucleotides (ASO) are taken up into cells by an endocytic process via interaction with proteins 
expressed on the surface of cells (Koller et al. 2011). The ASOs escape the endosome and enter the nucleus, 
where they bind to the SMN2 pre-mRNA. Binding of the ASO to the RNA displaces an hnRNP protein that 
normally represses splicing of exon 7, resulting in the production of a mature mRNA that includes exon 7, 
which is translated into the full-length SMN protein (Rigo et al. 2012). (Taken from (Rigo et al. 2012).) 
The mechanism(s) by which ASOs enter cells include at least two endocytic uptake 
mechanisms (Figure 5; (Koller et al. 2011; Geary et al. 2009), but overall remains poorly 
understood. Binding of the ASO to the RNA displaces an hnRNP protein that normally 
represses splicing of exon 7, resulting in the production of a mature mRNA that includes 
exon 7, which is translated into the full-length SMN protein (Rigo et al. 2012). 
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Over the last decade, several groups tried to optimize the efficacy of ASO-treatments in 
order to make it more applicable and attractive for use in SMA therapy. Therefore, certain 
parameters needed to be taken in consideration: structure of the ASO drug molecule, 
delivery to the CNS by crossing the blood-brain barrier (BBB), and especially in mouse pre-
clinical studies overcoming the known difficulties of multi-organ failure and diminishing tail 
and ear necrosis of the severely affected and most commonly used Δ7 and Taiwanese SMA 
mouse models (see also chapter 1.1.6). To achieve this, ASOs that block ISS-N1 (an intron 
7 intronic splicing silencer in the human SMN1/2 genes) and strongly enhance SMN2 exon 
7 inclusion in cultured patient fibroblasts (Singh et al. 2006) were systematically analyzed in 
cell-free splicing and in cultured cells (Hua et al. 2007; Hua et al. 2008). In 2009, a 2′-O-
methyl (2′-OMe) phosphorothioate ASO (Figure 4) targeting ISS-N1 was directly delivered 
into the CNS by repeated neonatal intracerebroventricular (ICV) injections in the Δ7 SMA 
mouse model (Williams et al. 2009). They reported a small increase in SMN protein and full-
length (FL) SMN2 mRNA in the spinal cord, as well as improvements in weight gain and the 
righting response. However, only one dosing regimen was tested, an effect on survival was 
not assessed, and several ASO-treated and control mice died prematurely (Williams et al. 
2009). 
The lead ASO (2′-O-(2-methoxyethyl) (MOE) ASO (#10–27), Figure 4) promotes efficient 
SMN2 exon 7 inclusion in the liver and kidneys of transgenic mice after systemic 
administration, but not in the spinal cord (Hua et al. 2008) owing to a lack of distribution 
across an intact BBB (Geary et al. 2003). Via ICV infusion in the CNS of adult type III SMA 
mice (Hsieh-Li et al. 2000) this MOE ASO had been characterized. In this study, they 
improved survival issues in mice with very short life spans, facilitated accurate 
measurements of mRNA splicing as well as long-term efficacy and metabolism of the ASO 
(Hua et al. 2010). The ASO promoted very efficiently expression of FL-SMN2 mRNA and 
protein in the spinal cord, including MNs. Remarkably, the effect persisted for several 
months after ICV infusion for only seven days. Validation of the mechanism of action as well 
as pharmacokinetic and pharmacodynamic profiles of the ASO allowed them to test its 
therapeutic efficacy by using a single embryonic or neonate ICV injection in the mild SMA 
mouse model (Hua et al. 2010) and thereby showed that the ASO can successfully rescue 
the distal tissue necrosis phenotype in the type III mouse model. This demonstrates that this 
MOE ASO is a promising drug candidate for SMA therapy. Additional findings of these group 
revealed that ASO only delivered into the CNS, efficiently corrected SMN2 exon 7 splicing 
in the spinal cord and led to a striking increase in SMN protein levels, but modestly extended 
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the median survival to 16 days, with a single pup surviving for one month (Hua et al. 2011). 
In marked contrast, systemic treatment with two subcutaneous injections resulted in a 
median survival of 108 days. Combining ICV and subcutaneous ASO injections further 
increased the median survival to 173 days; and additional subcutaneous injections at P5-
P7, after the initial subcutaneous injections at P0-P3, extended the median survival to 137 
days (Figure 6 and (Hua et al. 2011)). For the present study, we used these findings as a 
starting point for dosage optimization of the SMN-ASO to successfully generate an 
intermediate SMA mouse model by subcutaneously injecting suboptimal doses (10 – 50 µg) 
of this MOE SMN-ASO (see also 5.3). 
 
Figure 6: Systemic versus ICV ASO-10-27 injections in SMA mice. Survival curves after SC administration 
with saline (SC0, n=26) or ASO (SC50, n=12) twice between P0 and P3. SC50-SC50 (n=14) mice received 
two additional SC injections at P5-P7. Het-SC-ICV (n=13) and SC50-ICV20 (n=18) were heterozygous and 
SMA mice, respectively, that received combined P1 ICV and P0-P3 SC injections. Each SC injection dose was 
50 μg/g. P<0.0001 for all groups versus SC0. P<0.0001 for all groups versus SC0. (Modified from (Hua et al. 
2011).) 
1.2 DEVELOPMENT OF THE NEUROMUSCULAR SYSTEM 
As briefly mentioned in section 1.1.5.2, the neuromuscular junction (NMJ) is the connection 
between axon and muscle. The communication between nerve and muscle is ensured 
through neurotransmitter release from the presynaptic nerve terminal and receptor mediated 
signal transduction at the postsynapse. The most striking disease features in SMA mice are 
malformation and dysfunction of the NMJ. These defects are then followed by MN loss in 
the ventral horns of the spinal cord (Kariya et al. 2008; Kong et al. 2009). It has been 
reported that severely affected Taiwanese mice displayed no MN loss before P8 (Fayzullina 
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and Martin 2016). Nonetheless, as there is also evidence of MN loss starting at P4 in very 
severely affected Δ7 SMA mice (Mentis et al. 2011; Le et al. 2005), it still remains unclear 
whether this ‘dying-back mechanism’ should be considered as the only mechanism in SMA 
pathology or whether MN loss can proceed or occur in parallel to NMJ pathology. In SMA 
pathology, NMJ abnormalities include both pre- and postsynaptic alterations. Among these 
are abnormal neurofilament (NF) accumulation in the presynaptic nerve terminals, 
pronounced axon routing and arborization deficits (Rajendra et al. 2007), decreased amount 
of neurotransmitter released per action potential (quantum content, QC), reduced 
postsynaptic size with immature plaque-like AChRs (Kariya et al. 2008) and reduced post-
synaptic currents (Torres-Benito et al. 2012). Therefore, an overview about fundamental 
processes driving axon growth and specification (axonal pruning) as well as NMJ 
development and refinement will be given below. 
1.2.1 Axonal pruning and NMJ refinement 
A delay of axon withdrawal from the NMJ during the process of axonal pruning in a PLS3 
overexpressing SMA mouse has been described by (Ackermann et al. 2013). The underlying 
mechanism of this developmental process is briefly summarized below. Axonal pruning is a 
mechanism to selectively remove exuberant neuronal branches and connections during 
developmental stages of the nervous system to ensure structural of functional properties of 
the neuronal circuitry (Low and Cheng 2006). During NMJ development, numerous nerve 
terminals innervate individual AChR clusters. For proper axonal pruning, all but one 
presynaptic connection are removed, until every endplate gets innervated by only one single 
motor nerve ending (Lichtman and Colman 2000). There are two possible mechanisms, 
which have been described previously, to explain the process of axonal pruning. One of 
them is the so-called axon retraction, in which axonal contents are believed to be shuttled 
to other axon branches but so far, it has never been reported to occur at the neuromuscular 
junction (Bishop et al. 2004). Interestingly, NMJs in neonatal mice showing signs of 
abnormal ultrastructure were observed during the period of synapse elimination (Rosenthal 
and Taraskevich 1977). The second possible process is the classical Wallerian-type 
degeneration. During this kind of mechanism the entire axon arbor is removed rather than a 
subset of axons, which also has not been observed at the NMJ. Another concept of this 
process is termed axosome shedding (Bishop et al. 2004), in which axons are retreated and 
leave behind dismantled bulbs at their tips, which get removed as they get subdivided into 
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smaller remnants, termed axosomes. Previous findings of Schwann cells, which 
incorporated axosome material, support the idea of axosome shedding as they actively drive 
axonal recycling (Bishop et al. 2004). Nonetheless, on molecular level the process of axonal 
pruning is still poorly understood and further investigations are inevitable (Vanderhaeghen 
and Cheng 2010). 
1.2.2 Influence of Actin on the Motor Neuron Integrity 
Neurotransmitter release at the presynaptic terminals is a very complex process controlled 
by cytoskeletal dynamics. The actin cytoskeleton is important for cell shape, movement, 
signalling and transport of molecules into the cell (Blanchoin et al. 2014). Within the neuronal 
circuitry actin is involved in transport of synaptic vesicles (SVs) towards the active zone, as 
well as endocytic and exocytic pathways within the synapse. Overexpression of PLS3 – an 
actin-binding and -bundling protein – results in increased presynaptic nerve arborization and 
AChR clustering at the NMJ. Furthermore, PLS3 delays axonal pruning, indicating that PLS3 
positively influences the axonal integrity (Ackermann et al. 2013). As PLS3 has an actin-
binding and -bundling function, it is highly interesting to understand the connection between 
actin and the MN integrity, which in turn also highlights some of the physiological 
improvements of our mouse model (5.3 and 5.4). 
Growth cones are the starting points of axonal outgrows. Actin polymerization is the main 
trigger for axonal outgrowth at the growth cones. Cofilin, which is also present at the growth 
cones has an actin destabilizing effect, as it localizes to the pointed (-) end of actin filaments, 
thereby depolymerizing actin (Pak et al. 2008). Previous studies have demonstrated, that 
axonal outgrowth is strongly dependent on the condensation state of the actin cytoskeleton 
at the growth cones. Indeed, less condensed actin supports axonal outgrowth (Bradke and 
Dotti 1999; Kunda et al. 2001). As already mentioned above (1.1.5.2), β-actin mRNA has 
been shown to be decreased in the growth cones of MNs derived from SMA mice and SMN-
depleted PC12 cells (Rossoll et al. 2003). This indicates that the amount of actin molecules 
is significantly decreased in SMA growth cones, which are moreover significantly smaller 
compared to controls. Additionally, the connection between actin filaments, which can be 
mediated by additional proteins through actin-binding and -bundling abilities, can be 
important for cytoskeleton dynamics and thus for axonal growth. Besides the actin- bundling 
protein PLS3, there are several additional bundling proteins that are located in the growth 
cones including α-actinin, fascin, CamKII, Myosin, AbLIM, Filamin (Oprea et al. 2008; Dent 
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and Gertler 2003; Letourneau and Shattuck 1989; Okamoto et al. 2007). Therefore, the actin 
cytoskeleton and its network are fundamental for axonal outgrowth and maintenance. 
1.3 PLS3 – A FULLY PROTECTIVE MODIFIER OF SMA 
Phenotypical variability among patients with genetically caused diseases is very common. 
Extrinsic as well as intrinsic genetic factors might influence the severity of the genetic 
disease. Genetic modifying genes can have a huge impact on the outcome of the disease 
phenotype. Therefore, they also offer a great possibility to investigate and understand 
pathomechanisms of genetic diseases in more detail by analyzing common downstream 
pathways of the disease-causing gene and the modifier. For a long time, SMN2 was the only 
known SMA-modifying gene with a strongly inverse correlation of SMN2 copy number and 
SMA severity (Feldkotter et al. 2002). In most SMA families, high similarities were observed 
between the siblings with the same homozygous SMN1-deletion and identical SMN2 copy 
number (Feldkotter et al. 2002; Rudnik-Schöneborn et al. 1994). However, so-called 
discordant families (Figure 7) with individuals having a homozygous deletion of SMN1 have 
been reported to be completely healthy, whereas members of the same family carrying the 
identical genotype show SMA symptoms according to the SMN2 copy number (Brahe et al. 
1995; Cobben et al. 1995; Hahnen et al. 1995; Wang et al. 1996). Therefore, it has been 
speculated that other modifying factors might compensate for the loss of SMN1 in unaffected 
siblings (Helmken and Wirth 2000; Helmken et al. 2003). 
The actin-filament-bundling protein PLS3 was identified as the first SMN-independent SMA 
modifying protein besides SMN2 in a total of seven discordant families (Oprea et al. 2008; 
Heesen et al. 2016). By using transcriptome-wide differential gene expression analysis, 
PLS3, which is also named T-plastin, fimbrin or plastin 3 (Lin et al. 1988), was identified 
within these discordant families in nine fully asymptomatic females with homozygous 
deletion of SMN1 and an identical number of SMN2 copies as their affected siblings (mostly 
3 – 4, reflecting SMA type III). This analysis was carried out with RNA from lymphoblastoid 
cell lines (Oprea et al. 2008). 
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Figure 7: PLS3 overexpression in discordant families. Six discordant families in which PLS3 were shown 
to be upregulated at RNA and protein levels. PLS3 shows a sex dependent SMA rescue in these families. 
(Taken from (Oprea et al. 2008).) 
PLS3 comprises of 16 exons and produces three mRNA transcript variants. Splice variants 
1 and 2 encode for exactly the same 1893 bp transcript. Splice variant 3, uses a different in-
frame splice site in the coding region, producing a transcript of 1812 bp in size. Besides 
PLS3, the human homologous genes L-plastin (PLS1) and I-plastin (PLS2) exist, which are 
located on chromosomes 3 and 13, respectively (Lin et al. 1993a; Lin et al. 1993b; Lin et al. 
1994). All plastins are highly conserved from lower eukaryotes to humans, reflecting their 
importance in every cell type (Delanote et al. 2005). It has been revealed by pull-down 
experiment that SMN and PLS3 proteins do not show a direct interaction. This led to the 
conclusion that PLS3 does not exert its rescuing effect through the SMN protein but rather 
a downstream effect influencing the stabilization of the actin cytoskeleton in axons (Oprea 
et al. 2008). 
The fact that all asymptomatic SMN1-deleted individuals were women might be explained 
by the location of PLS3 on the X-chromosome (Xq23), making an incomplete X-inactivation 
a possible mechanism behind the PLS3 upregulation. Surprisingly, a few independent male 
SMA patients in this study revealed a similarly high PLS3 expression compared with the 
asymptomatic women but failed to be protected (Oprea et al. 2008). However, the location 
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of the PLS3 gene on the X-chromosome and its gender specific rescuing effect suggest a 
possible hormone related regulatory mechanism. PLS3 was found to be overexpressed in 
asymptomatic SMN1-deleted individuals only in blood but not in fibroblasts, which suggests 
a tissue-specific regulation. Moreover, generation of induced pluripotent stem cells (IPSCs) 
from fibroblast cell lines allowed the differentiation into MNs and thus the analysis of PLS3 
expression in the target cell type (Heesen et al. 2016). In cultures of these differentiated 
MNs, SMA III and asymptomatic siblings exhibited slightly higher but insignificant elevated 
SMN expression than control levels. This data excludes SMN levels as the reason for SMA 
protection in asymptomatic siblings. In contrast, PLS3 was significantly upregulated in mixed 
MN cultures from asymptomatic individuals pinpointing a tissue-specific regulation. 
Interestingly, PLS3 is abundant in growth cones of asymptomatic MN cultures as compared 
to SMA III siblings and controls. This implies an important role of PLS3 in neuromuscular 
synapse formation and maintenance and underlines the role of PLS3 as genuine protective 
modifier in SMA. 
PLS3 is highly expressed in fetal and adult human spinal cord, as well as brain and muscle. 
Most strikingly, PLS3 overexpression led to a full rescue of axon defects in smn depleted 
zebrafish (Danio rerio) embryos (Oprea et al. 2008). In another study, behavioural analysis 
in smn mutant fish showed a reduced spontaneous swimming and truing. The transgenic 
overexpression of PLS3 in MNs was able to rescue the neuromuscular defect and 
corresponding movement phenotype in smn mutant fish (Hao le et al. 2012). Rescuing 
experiments with different parts of the PLS3 protein indicate that the Ca2+-binding EF hand 
domain of PLS3 is able to rescue axonal phenotype in smn mutant fish ((Lyon et al. 2014) 
and Figure 8). 
To further investigate the influence of the PLS3 overexpression on the SMA phenotype in 
the mammalian system, a conditional PLS3 overexpressing mouse model was generated 
(Ackermann et al. 2013). In these PLS3 transgenic SMA mice the motor axon inputs at the 
NMJ were significantly increased compared to endplates in SMA mice, which are only poorly 
or not at all innervated. During the process of axonal pruning, exuberant neuronal branches 
are removed and endplates become innervated by a single axon. Delayed axonal pruning 
in the PLS3 overexpressing mice finally leads to prolonged poly-innervation of endplates 
and maturation of NMJs. PLS3 overexpression improves neuromuscular connectivity as well 
as neurotransmitter release at the NMJ (Ackermann et al. 2013). Furthermore, PLS3 
overexpression restores the disturbed F-Actin amount and the synaptic vesicle organization 
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in SMA mice (Ackermann et al. 2013). Despite all these improvements, PLS3 
overexpression did not have a strong influence on the survival of these severely affected 
SMA mice, which can be due to multi-organ dysfunctions in this SMA mouse model 
(Ackermann et al. 2013; Schreml et al. 2013). Therefore, in the present study, we will focus 
on diminishing these inner organ defects and mimicking the situation of the asymptomatic 
SMN1-deleted individuals, to finally show the unrestricted PLS3 rescuing effect as described 
in chapter 2. 
1.3.1 PLS3 protein 
The PLS3 protein consists of 630 amino acids and is approximately 70 kDa in size. N-
terminally and as already mentioned, PLS3 contains a calcium-binding domain consisting of 
a pair of EF hands with a helix-loop-helix structure. Additionally, it possesses a pair of actin 
binding domains (ABDs) composed out of two calponin homology (CH) domains (Figure 8) 
(Matsudaira 1994), which are located at the C-terminus. 
 
Figure 8: PLS3 protein structure: The 630 aa long protein has two N-terminal EF-hand domains followed by 
two actin binding domains (ABD1 and ABD2), each consisting of two calponin homology domains. 
The EF-hand domain structure has high similarity with a spread thumb and forefinger of a 
hand. Calcium ions are coordinated by ligands within the loop and binding of Ca2+ to this 
motif might regulate PLS3 activity in actin bundling (Hanein et al. 1998). Ca2+ thereby acts 
as a negative regulator for PLS3 to interact with actin. Another study, using cryo-electron 
microscopy (EM) revealed the interaction of F-actin with the ABD2 domain of PLS2 (Galkin 
et al. 2008). Interestingly, PLS3 was found to interact with ataxin-2 (ATX2), suggesting a 
-N C- 
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possible role in regulation of RNA metabolism and translation. Noteworthy, ATX2 is known 
to interact with cytoplasmic poly(A)-binding protein (PABP), which is involved in translation 
initiation and mRNA decay regulation, as well as forming parts of stress granules (Ralser et 
al. 2005a).Overexpression of ATX2 increases PLS3 levels specifically in comparison to 
other plastins (Ralser et al. 2005b). 
1.4 ENDOCYTOSIS – AN AFFECTED MECHANISM IN SMA 
Because PLS3 knockout in yeast impairs endocytosis (Kubler and Riezman 1993), we 
hypothesized that disturbed endocytosis might be a key cellular mechanism underlying 
impaired neurotransmission and neuromuscular junction maintenance in SMA. Our recently 
published data as well as analyses done in the present study (see also chapter 5.13) 
demonstrate very nicely (in vitro and in vivo) how the process of endocytosis is disturbed in 
SMA (Hosseinibarkooie et al. 2016). As endocytosis is deeply connected to signalling, cell 
dynamics, growth, regulation, and defence, endocytic processes are linked to almost all 
aspects of cell life and disease. To better understand this very complex process and its 
regulations, an overview about endocytic pathways is given in the following. Endocytosis is 
the general term for energy-dependent internalization of fluid, solutes, macromolecules, 
plasma membrane components, and particles by the invagination of the plasma membrane 
and the formation of vesicles and vacuoles through membrane fission. By sorting, 
processing, recycling, storing, activating, silencing, and degrading incoming substances and 
receptors, endosomes are responsible for regulation and fine-tuning of numerous pathways 
in the cell (Huotari and Helenius 2011). Chemical synaptic transmission is mediated by 
neurotransmitters that are released by Ca2+-triggered synaptic vesicle exocytosis (Deak et 
al. 2009). As many of the NSF attachment proteins (SNAPs) and SNAP receptors (SNAREs) 
are involved in both, endocytic and exocytic processes, the whole cycle should be 
considered as disturbed in SMA and further investigations are necessary to better 
understand the fine-tuning between those two processes. Interestingly, in this context is the 
role of Munc18-1-SNARE complexes that may create a central event in the priming reaction 
that makes docked synaptic vesicles readily releasable (Deak et al. 2009). To better 
understand the connecting mechanisms, Figure 9 illustrates several types of pathways by 
which nanoparticles can enter (endocytosis) and exit (exocytosis) the cell. The endocytosis 
pathways are classified into clathrin- and caveolae-mediated endocytosis, phagocytosis, 
macropinocytosis, and pinocytosis. Many types of cells use the clathrin- and caveolae-
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mediated endocytosis pathways to internalize nanoscale materials, including viruses and 
nanoparticles (Pelkmans et al. 2001; Wang et al. 2009). Most importantly, nanoparticles are 
internalized by direct coating with the plasma proteins when exposed to physiological 
solutions. The phagocytosis pathway is used when phagocytic cells internalize foreign 
materials with sizes larger than 0.5 µm (Young 2006). The phagocytosis pathway is actin-
dependent and restricted to specific phagocytes, such as macrophages, dendritic cells, and 
neutrophils. The macropinocytosis pathway is a non-specific process to internalize fluids 
and particles together into the cell, whereas the pinocytosis pathway absorbs biological 
fluids from the external environment of a cell (Geiser 2010). These pathways are very 
important to translocate single nanoparticles with sizes below 10 nm into the cell. The 
exocytosis pathways are classified into lysosome secretion, vesicle-related secretion, and 
non-vesicle-related secretion (Oh and Park 2014). 
 
Figure 9: Schematic of endocytosis and exocytosis patterns of nanoparticles. Nanoparticles enter the 
cell via four types of pathway: clathrin/caveolar-mediated endocytosis, phagocytosis, macropinocytosis, and 
pinocytosis. Nanoparticles exit the cell via three types of pathway: lysosome secretion, vesicle-related 
secretion, and non-vesicle-related secretion. MVBs: multivesicular bodies. (Taken from (Oh and Park 2014).) 
As mentioned above, endocytosis is actin-dependent and therefore a lot of research had 
been done on the role of actin as an important player in endocytosis. Actin is no longer 
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regarded as a passive barrier that must be removed to allow endocytosis to proceed but to 
assist the remodelling of the cell surface to allow inward movement of vesicles (Smythe and 
Ayscough 2006). Without the appropriate lipid environment, membrane curvature, which is 
crucial for vesicle formation, cannot occur. However, membrane lipids also regulate the 
activity of several actin-binding proteins, including capping protein (Amatruda and Cooper 
1992). In this context, also the role of Plastin 3 and its rescuing effect on disturbed types of 
endocytosis (clathrin- and non-clathrin-mediated and activity-dependent bulk endocytosis) 
in SMA mice were further investigated in the present study ((5.13) and (Hosseinibarkooie et 
al. 2016)). 
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2. Aims 
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder 
characterized by the loss of α-motor neurons in the anterior horns of the spinal cord, thus 
leading to atrophy and paralysis of proximal symmetrical muscles. Patients suffering from 
SMA, in almost all cases, show homozygous deletion of the survival of motor neuron 1 gene 
(SMN1) and the severity of the disease is inversely correlated with the copy number of the 
survival motor neuron 2 gene (SMN2) the main SMA modifying gene. 
Our group identified Plastin 3 (PLS3) as a first independent of SMN protective SMA 
modifying gene, showing high expression in asymptomatic homozygously SMN1-deleted 
siblings of discordant SMA families. PLS3 has been found to be expressed at very high 
levels in human spinal cord. Cell culture experiments as well as in vivo SMA animal models 
(zebrafish and mouse) revealed that PLS3 overexpression rescues the axonal outgrowth 
phenotype (Oprea et al. 2008). We subsequently generated a transgenic mouse model 
overexpressing PLS3. Severely affected SMA mice overexpressing PLS3 heterozygously 
showed improved motoric abilities as a consequence of increased neuromuscular junctions 
(NMJ) and muscle fibre size as well as an increase of proprioceptive input on motor neuron 
(MN) soma. Most importantly, PLS3 overexpression delayed axon pruning and improved 
connectivity of the presynapse to motor endplates. Nonetheless, survival was subtly 
extended by only a few days, as a result of massive inner organ impairment in SMA mice 
which was not rescued by PLS3 overexpression (Ackermann et al. 2013). 
The major aim of this study is to conclusively confirm that PLS3 overexpression rescues 
survival and multi-organ dysfunction on a SMN-ASO-induced intermediate SMA mouse 
model and thereby increases NMJ size, number of proprioceptive inputs, MN soma size, 
endocytic uptake, and motoric ability (grip strength force and tube test) in the intermediate 
SMA mouse model. 
To do so, we decided to use a combinatorial therapy with a suboptimal dose of SMN 
antisense oligonucleotide and PLS3 overexpression – a situation resembling the human 
condition in asymptomatic SMN1-deleted individuals. 
The following steps were proposed: 
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1. Generation of two congenic SMA mouse models that will allow us to track back the 
effect of the modifier and exclude additional factors that might influence the SMA 
phenotype. 
2. Generation and detailed analysis of SMA mice expressing PLS3 homozygously. 
3. Development of an intermediate SMA mouse model by using different suboptimal 
doses of SMN-ASOs injected in the severe SMA mouse model. Two parameters, 
which may influence the outcome of the phenotype, postnatal day of injection and 
mode of ASO delivery, will be investigated, in order to identify the most appropriate 
combination. 
4. Understanding the influence of low dose SMN-ASOs on the outcome of the SMA 
phenotype by using two different congenic strains: C57BL/6N and FVB/N. 
5. Generation of SMA mice treated with suboptimal SMN-ASO doses and 
overexpressing PLS3 heterozygously and homozygously to analyse the impact of 
PLS3 in an intermediate SMA mouse model. 
6. Detailed analysis of these mice including survival, weight progression, motoric 
abilities (tube test, righting reflex test, grip strength test) development of inner organs 
(heart, lung, intestine), analyses of MNs, NMJs and muscles by histological and 
immunofluorescent analyses, expression analysis of SMN and PLS3. 
7.  Analysis of endocytosis in SMA-PLS3 and SMA murine embryonic fibroblasts 
(MEFs). 
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3. Materials 
3.1 DEVICES AND UTILITIES 
Table 1: Devices and Utilities 
Type of device Designation Manufacturer 
Apotome Apotome.2 Zeiss 
Balance EW Kern 
Balance Adventurer Ohaus 
Balance (fine scale) ARJ 120-4M Kern 
Bipolar electrode holder MEW-F15B Warner Instruments 
Borosilicate glass tubes GB150T-8P Science Products GmbH 
Centrifuge Allegra X22-R Beckmann Coulter 
Centrifuge Avanti J-20XPI Beckmann Coulter 
Centrifuge 5415R Eppendorf 
Centrifuge 5415D Eppendorf 
Centrifuge Galaxy Mini VWR 
Electrophoresis chamber E-H6 Febikon 
Electrophoresis chamber E-PB 0 Febikon 
Electrophoresis chamber Mini-Protean 3 cell BioRad 
Electrophoresis chamber Mini-Protean Tetra System BioRad 
Fluorescence lamp HXP 120 C Zeiss 
Freezer (-80°C) HERA freeze Heraeus 
Gel documentation ChemiDoc XRS BioRad 
Gel documentation Gel Doc XR+ BioRad 
Grip strength meter 303500 TSE Systems 
Hamilton needle (30/30/4) 7803-07 Hamilton 
Hamilton syringe RN 5 µL HAMI7634-01 Hamilton 
Heating block DB 3D Techno 
Heating magnetic stirrer MR3001 Heidolph 
Homogenizer T10 basic, Ultra Turrax IKA 
Homogenizer Precellys 24 Peqlab 
Ice machine AF 80 Scotsman 
Incubator Innova 44 New Brunswick Scientific 
Incubator Innova 4230 New Brunswick Scientific 
Incubator, tissue culture HERA cell 150 Heraeus 
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Type of device Designation Manufacturer 
Laminar airflow cabinet HERA safe Heraeus 
Light source (Fibre optic) KL 1500 LCD Leica 
Microplate reader Safire2 Tecan 
Microscope (BF) Axioshop 2 Zeiss 
Microscope (Confocal) Meta 510 Zeiss 
Microscope (Fluorescence) Imager M2 Zeiss 
Microscope (stereo) S8AP0 Leica 
Microscope camera AxioCam MRm Zeiss 
Microscope camera AxioCam ICc 1 Zeiss 
Microscope camera AxioCam ERc 5s Zeiss 
Microtome RM2255 Leica 
Microwave R-898(AL)-A Sharp 
Orbital Shaker 3015 GFL 
pH meter inoLab pH level 1 WTW 
Photometer BioPhotometer Eppendorf 
Photometer NanoDrop 1000 Peqlab 
Pipette Research (2.5/10/20/100/ 
200/1000/5000 µL) 
Eppendorf 
Pipette (automatic) Research Pro (10/100 µL) Eppendorf 
Pipette (repetitive) Multipette Plus Eppendorf 
Pipettor Pipetboy acu Integra biosciences 
Power supply PowerPac Basic BioRad 
Power supply PowerPac HC BioRad 
Power Supply 252 Zeiss 
Real-time Thermocycler Light Cycler 1.5 Roche 
Roll incubator SRT9 Stuart 
Roll incubator SRT6D Stuart 
RotaRod RotaRod advanced Systems TSE Systems 
Safety gas-burner Fireboy Plus IBS 
Shaker + heating block HLC Ditabis 
Speed Vac Concentrator 5301 Eppendorf 
Thermocycler DNAengine Tetrad2 MJ Research 
Thermocycler DNAengine Dyad MJ Research 
Thermocycler S1000 BioRad 
Thermocycler C1000 Touch BioRad 
Tissue processor TP1028 Leica 
Transfer System Trans-Blot Turbo BioRad 
Ultrasonicator Bioruptor Diagenode 
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Type of device Designation Manufacturer 
Universal digital stimulator MS501 custom-made (Uni Köln) 
Universal stimulus isolator MI401 custom-made (Uni Köln) 
Vacuum pump PM12640-026.3 Biometra 
Vortex 444-1372 VWR 
Water bath 1083 GFL 
 
3.2 CHEMICALS 
Table 2: Chemicals 
Chemical Manufacturer 
2-Mercaptoethanol (99%, p.a.) AppliChem 
2-Propanol (≥ 99.5%) AppliChem 
Acetic acid AppliChem 
Acetone AppliChem 
ADVASEP-7 Sigma 
Agarose (low melting) Biozym 
Agarose for routine use Sigma-Aldrich 
Ammonium persulfate AppliChem 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue AppliChem 
Chloroform AppliChem 
Citrate AppliChem 
Control-ASO 439272 IONIS Pharmaceuticals 
Coomassie Brilliant Blue R-250 AppliChem 
D-glucose AppliChem 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Disodium hydrogen phosphate (p.a.) AppliChem 
Dithiothreitol (DTT) AppliChem 
Ethanol (≥ 99.5%, p.a.) AppliChem 
Ethidium bromide (1% in H2O) AppliChem 
Ethylenediaminetetraacetic acid (EDTA) AppliChem 
FITC-Dextran Sigma-Aldrich 
FM1-43 Molecular Probes 
Formaldehyde (37%, p.a.) AppliChem 
Glycerol (86%, p.a.) AppliChem 
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Chemical Manufacturer 
Glycine AppliChem 
Hoechst Life Technologies 
Hydrochloric acid (37%, fuming) AppliChem 
Hydroxymethylaminoethane (Tris) AppliChem 
Isoamylalcohol AppliChem 
Methanol (≥ 99.9%, p.a.) AppliChem 
Milk powder (low fat) AppliChem 
Mowiol Roth 
Paraformaldehyde Fluka 
Phenol AppliChem 
SMN2-ASO 387954 IONIS Pharmaceuticals 
Sodium acetate AppliChem 
Sodium chloride (p.a.) AppliChem 
Sodium dihydrogen phosphate dihydrate (p.a.) AppliChem 
Sodium dodecyl sulfate (SDS, 10% in H2O) AppliChem 
Sodium hydroxide AppliChem 
Tertramethylethylenediamine (TEMED) AppliChem 
Triton X-100 AppliChem 
Trizma base Sigma-Aldrich 
Tween-20 (Polysorbate 20) AppliChem 
Water (HPLC grade) Sigma-Aldrich 
Xylene AppliChem 
 
3.3 KITS 
Unless noted otherwise, all kit-related procedures have been performed according to 
the manufacturer’s instructions. 
Table 3: Kits 
Name Manufacturer 
DNeasy Blood and Tissue Kit Qiagen 
gDNA Blood & Tissue Kit Qiagen 
Light Cycler Fast Start DNA Master SYBR green I Roche 
QIAshredder Qiagen 
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Name Manufacturer 
Quant-iT RiboGreen RNA assay Kit Life Technologies 
QuantiTect Reverse Transcription Kit Qiagen 
RNeasy Mini Kit Qiagen 
Superscript II Reverse Transcription Kit Life Technologies 
 
3.4 REAGENTS AND EQUIPMENT 
3.4.1 Reagents 
Table 4: Reagents 
Reagent Manufacturer 
Quick-Load® Purple 2-Log DNA Ladder New England Biolabs 
AquaPlus Mix 30% (29:1 Acrylamide/Bisacrylamide) AppliChem 
Bradford reagen AppliChem 
Complete Mini Protease Inhibitors Roche 
Eosin-Y solution Sigma-Aldrich 
Eukitt mounting medium Fluka 
Mayer’s Hematoxylin Sigma-Aldrich 
OneTaq® Quick-Load 2X Master Mix with Std.-Buffer New England Biolabs 
Page Ruler Prestained Protein Ladder Thermo 
PBS (10x) VWR 
Ponceau S Sigma Aldrich 
QIAzol Lysis Reagent Qiagen 
Restore Western Blot Stripping Buffer Thermo 
Ripa buffer Sigma-Aldrich 
Super Signal West Pico ECL Substrate Thermo 
TBE (10x) Sigma-Aldrich 
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3.4.2 Enzymes and growth factors 
Table 5: Enzymes and growth factors 
Type Name Manufacturer 
Enzyme DNAse I AppliChem 
Enzyme Proteinase K AppliChem 
Enzyme Recombinant Taq DNA Polymerase Life Technologies 
Enzyme RNase A Sigma-Aldrich 
Growth factor Murine GDNF Pepro Tech 
Growth factor Human BDNF Pepro Tech 
Growth factor Rat CNTF Pepro Tech 
 
3.4.3 Cell culture reagents and media 
Table 6: Cell culture reagents and media 
Type Name Manufacturer 
Antibiotic G418 (Geniticin) Sigma-Aldrich 
Antibiotic Penicillin/Streptomycin Life Technologies 
Antibiotic Zeocin Life Technologies 
Coating solution Laminin Thermo 
Coating solution Poly-D-lysine Sigma-Aldrich 
Fungicide Amphotericin B Promocell 
Medium DMEM Life Technologies 
Medium DMEM transparent Life Technologies 
Medium Glutamax Life Technologies 
Medium HBSS Life Technologies 
Medium PBS Life Technologies 
Medium Neurobasal Life Technologies 
Medium Opti-MEM Life Technologies 
Medium Trypsin/EDTA Life Technologies 
Serum Fetal Bovine Serum Biochrom 
Serum Horse Serum Biochrom 
Supplement B27 Life Technologies 
Supplement BSA Sigma-Aldrich 
Supplement Glucose AppliChem 
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Type Name Manufacturer 
Supplement Trypsin AppliChem 
Supplement Trypsin Inhibitor AppliChem 
 
3.4.4 Equipment for laboratory mouse work 
Table 7: Equipment for laboratory mouse work 
Type Name Manufacturer 
Cell strainer Nylon mesh, 70 µm BD Falcon 
Ear tag applicator 1005-s1 National Band & Tag Co. 
Ear tags 1005-1 National Band & Tag Co. 
Forceps DB047R Aesculap 
Forceps Dumont #5 (11252-20) Fine Science Tools 
Forceps Dumont #5/45 (11251-33) Fine Science Tools 
Forceps Dumont #55 (11255-20) Fine Science Tools 
Forceps FM002R Aesculap 
Pins Minutien Plano 
Scissors BC100R Aesculap 
Scissors BC321R Aesculap 
Scissors BC8641R Aesculap 
Silicone Elastomer Silgard 184 Sigma-Aldrich 
 
3.5 SOLUTIONS AND MEDIA 
Table 8: Solutions and Media 
Name Composition 
Citrate buffer 10 mM citrate; pH 6 
DEPC H2O 0.1% (v/v) DEPC in H2O; stir over night; autoclave 
DNA sample buffer, 10x 100 mM EDTA (pH 8); 1% (w/v) SDS; 
50% (v/v) Glycerin; 0.1% (w/v) Bromophenol blue; 
0.25% (w/v) Xylene cyanol 
dNTP Mix (1.25 mM per dNTP) 5 μl dATP; 5 μl dCTP; 5 μl dGTP; 5 μl dTTP; 480 μl H2O 
Lysis buffer (tissue) 200 mM NaCl; 100 mM Tris-HCl; 5 mM EDTA; 
0.2% (w/v) SDS; pH 8.5; 200 μg/ml proteinase K (fresh) 
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Name Composition 
Paraformaldehyde (4%) 4% paraformaldehyde, dilute in 30 ml H2O at 60°C; 
add 1 M NaOH to clear the solution; cool down and 
filter; add 50 ml 2x PBS, pH 7.4 
Resolving gel (SDS-PAGE), 12% 3.3 ml H2O; 4 ml 30% acrylamide mix; 
2.5 ml 1.5 mM Tris pH 8.8; 100 μl 10% SDS; 
100 μl 10% APS; 4 μl TEMED 
SDS electrophoresis buffer, 10x 0.25 M Tris; 1.92 M Glycine; 1% (w/v) SDS; pH 8.3 
SDS sample buffer (2x) 0.757 g Tris-base; 20 ml glycerol; 
10 mg Bromophenol blue; 6 g SDS; ad 90 ml H2O; 
add 1/10 Vol. ß-ME before use 
Stacking gel (SDS-PAGE), 4% 1.4 ml H2O; 330 μl 30% acrylamide mix; 
250 ml 1.5 mM Tris pH 6.8; 20 μl 10% SDS; 
20 μl 10% APS; 2 μl TEMED 
TBST 0.5% (v/v) Tween-20 in TBS 
TE buffer 10 mM Tris; 1 mM EDTA; pH 8 
TE-4 buffer 10 mM Tris-HCl; 0.1 mM EDTA; pH 8 
Transfer buffer (Western Blot) 15 mM Tris-base; 150 mM Glycine; 20% (v/v) Methanol 
 
3.6 CELL CULTURE 
3.6.1 Cell lines 
The following cell lines were employed in this study: 
 MEFs: Cells were derived from mouse embryos (E13.5) and isolated as described in 
section 4.2.1. The embryos had been obtained from breedings of the severe SMA 
mouse model (Taiwanese SMA mice (Hsieh-Li et al. 2000)) with and without the 
disease modifier PLS3 (Ackermann et al. 2013). 
 MNs: Cells were derived from mouse embryos (E13.5) and isolated as described in 
section 4.2.2. The embryos had been obtained from breedings of the severe SMA 
mouse model (Taiwanese SMA mice (Hsieh-Li et al. 2000)) with and without the 
disease modifier PLS3 (Ackermann et al. 2013). 
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3.7 MOUSE INBREAD STRAINS 
The PLS3V5 transgene mouse model (Ackermann et al. 2013) were cross-bred with the 
severly affected SMA mouse model (Taiwanese SMA mice (Hsieh-Li et al. 2000)) to study 
the influence of PLS3 overexpression (OE) in SMA mice. For this purpose and using the 
Cre/loxP system, a V5-tagged version of human PLS3 was targeted into the murine Rosa26 
locus in order to ubiquitously or tissue specific overexpress PLS3. All animals were 
maintained either on a congenic C57BL/6N or FVB/N background. At first, the Taiwanese 
SMA mouse model was only available on FVB/N background, therefore we needed this 
mouse line to be crossed back for at least eight times in order to receive a SMA mouse on 
pure C57BL/6N background. So far, these mice are crossed back more than 20 generations. 
In the beginning of this study, the generation of the SMA-PLS3hom and HET-PLS3hom mice 
was necessary, as in previous experiments only SMA-PLS3het and HET-PLS3het mice had 
been used (Ackermann et al. 2013). 
3.8 ANTIBODIES 
3.8.1 Primary antibodies 
Table 9: Primary antibodies 
Antibody Host species Block
ing 
Dilution Incuba
tion 
Supplier Product 
α-β-actin mouse, monoclonal milk WB: 1:30,000 1 hour Sigma-Aldrich A5316 
α-ChAT goat, polyclonal BSA IHC/ICC: 1:300 o. n. Millipore AB144P 
α-NF mouse, monoclonal BSA IHC/ICC: 1:100 o. n. Hybridoma Bank AB_2314897 
α-PLS3 rabbit, monoclonal milk WB: 1:1,000 o. n. produced by AG Wirth N/A 
α-SV2 mouse, monoclonal BSA IHC: 1:100 o. n. Hybridoma Bank AB_2315387 
α-V5-HRP mouse, monoclonal milk WB: 1:3000 o. n. Life Technologies 46-0708 
α-VGlut1 rabbit, polyclonal BSA IHC: 1:300 o. n. Synaptic Systems 135303 
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3.8.2 Secondary antibodies 
Table 10: Secondary antibodies 
Antibody Host species Blocking Dilution Incubation Supplier Product 
α-goat IgG 
Alexa fluor 568 
donkey BSA 1:750 2 hours Life Technologies A11057 
α-mouse IgG 
Alexa fluor 488 
donkey BSA 1:500 2 hours Life Technologies A10667 
α-mouse IgG 
(HRP conjugate) 
goat milk 1:5,000 1 hour Immuno Research N/A 
α-rabbit IgG 
Alexa fluor 488 
donkey BSA 1:750 2 hours Life Technologies A21206 
α-rabbit IgG 
(HRP conjugate) 
goat milk 1:5,000 1 hour Cell signaling 7074S 
Bungarotoxin 
(BTX) 
None none 10 µL 
stock/7 mL 
PBS 
10 min Life Technologies B1601 
Phalloidin 
Alexa fluor 568 
none none 1:40 1 hour Life Technologies A12380 
 
3.9 OLIGONUCLEOTIDES AND PCR CONDITIONS 
All oligonucleotides used and optimized in this study are listed below. Amplicon defines the 
target of the PCR. Oligonucleotide sequences are listed in 5’ to 3’ direction, while forward 
primers are designated as fwd, reverse primers as rev. The given identification number 
corresponds to the in house primer database. Product gives the length of the PCR product 
in base pair. The column °C indicates the optimal annealing temperature. For genotyping 
35, for quantitative PRC 40 cycles had been used. 
3.9.1 Oligonucleotides for genotyping 
Genotyping of mice was performed as previously described using the following primers and 
conditions (Ackermann et al. 2013). 
Materials 41 
 
Table 11: Oligonucleotides for genotyping 
Inbred 
strain 
Amplicon Oligonucleotide 5'>3' ID# Name 
Annealin
g/ 
Amplico
n length 
SMA-Hung 
WT Smn 
fwd ATAACACCACCACTCTTACTC 3370 
HungSMA_mouse_
wt/Mut_fw_S1 59°C/ 
1050 bp 
rev GTAGCCGTGATGCCATTGTCA 3372 
HungSMA_mouse_
wt_rev_H1 
Hung KO 
fwd AGCCTGAAGAACGAGATCAGC 3371 
HungSMA_mouse_
wt_rev_S2 59°C/ 
950 bp 
rev ATAACACCACCACTCTTACTC 3370 
HungSMA_mouse_
wt/Mut_fw_S1 
hSMN2 tg 
fwd CGAATCACTTGAGGGCAGGAGTTTG 3375 
HungSMA_mouse_t
ghSMN2_fw_2F 59°C/ 
479 bp 
rev AACTGGTGGACATGGCTGTTCATTG 3376 
HungSMA_mouse_t
ghSMN2_rev_2B 
PLS3V5 PLS3V5 rec fwd AAAGTCGCTCTGAGTTGTTATC 3650 Typ_forw 56°C/ 
PLS3V5 
PLS3V5 rec rev GATATGAAGTACTGGGCTCTT 3649 Typ_rev_wt 380 bp 
PLS3V5 wt 
fwd AAAGTCGCTCTGAGTTGTTATC 3650 Typ_forw 56°C/ 
576 bp rev TGTCGCAAATTAACTGTGAATC 3648 TYP_rev_CAGS 
 
3.9.2 Oligonucleotides for quantitative PCR 
Primer usage for quantitative real-time PCR on the Roche Light Cycler 1.5. Quantitative 
real-time PCR was performed as previously described using the following primers and 
conditions (Riessland et al. 2010). 
Table 12: Oligonucleotides for quantitative PCR 
Name Oligonucleotide 5'>3' Product [bp] °C ID# 
SMN-FL-Δ7-fwd CCACCACCCCACTTACTATCA 236 62 1449 
SMN-FL-rev GCTCTATGCCAGCATTTCTCCT 236 62 3054 
SMN-FL-Δ7-fwd CCACCACCCCACTTACTATCA 236 61 1449 
SMN-Δ7 GCTCTATGCCAGCATTTCCATA 182 61 1450 
Gapdh GGCTGCCCAGAACATCATCC 169 63 3999 
Gapdh GTCATCATACTTGGCAGGTTTCTC 169 63 4000 
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3.10 SOFTWARE, WEB APPLICATIONS AND DATABASES 
3.10.1 Software 
Table 13: Software 
Name Purpose Manufacturer 
AutoStitch 2.2 Image processing (panoramic assembly) University of British 
Columbia 
EndNote X7 Reference management Thomson Reuters 
Excel 2007/2013 Plots, charts, data processing, statistics Microsoft 
Image J (Fiji) Image processing, Z-stacks, densitometric analysis NIH 
Mausoleum Laboratory mouse management Dr. Hanns-Eugen Stöffler 
Prism 7 Plots, charts, data processing, statistics GraphPad Software 
Pyrat Laboratory mouse management Scionics 
Light Cycler Software Quantitative real-time PCR analysis Roche 
Power Point 2007/2013 Image illustration Microsoft 
Quantity One 4.5.1 Densitometric analysis BioRad 
Word 2007/2013 Word processing Microsoft 
ZEN 2 Fluorescence imaging and analysis Zeiss 
 
3.10.2 Databases and web applications 
Table 14: Databases und web applications 
Name URL 
BfR http://www.animaltestinfo.de/antragsteller 
Ensembl http://www.ensembl.org/index.html 
Genecards http://www.genecards.org/ 
Ingenuity Systems http://www.ingenuity.com/ 
NCBI http://www.ncbi.nlm.nih.gov/ 
OligoCalc http://basic.northwestern.edu/biotools/OligoCalc.html 
Pubmed http://www.ncbi.nlm.nih.gov/pubmed 
UniProt http://www.uniprot.org/ 
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4. Methods 
4.1 WORKING WITH LABORATORY MICE 
4.1.1 Mouse experiments 
All procedures involving laboratory animals were performed according to the German laws 
of animal welfare and were approved by the ‘Landesamt fuer Natur, Umwelt und 
Verbraucherschutz NRW’ under the reference numbers 84-02.05.20.12.120, 84-
02.04.2014.A006 and 84-02.04.2015.A378. Animals used in this study were kept in the 
animal facility of the Institute for Genetics at the University of Cologne. 
4.1.2 Breeding of SMA-PLS3 and control mice 
The Taiwanese SMA mouse model FVB.Cg-Tg (SMN2)2Hung Smn1tm1Hung/J, stock 
number 005058 (here named SmnKO/KO;SMN2tg/tg) was purchased from Jackson Laboratory. 
In our laboratory, we backcrossed these mice for more than seven generations to obtain a 
congenic C57BL/6N background. We maintained the breeding colony by crossing 
SmnKO/KO;SMN2tg/tg mice and SmnKO/WT mice with WT mice. PLS3-overexpressing 
transgenic animals were used for generating SmnKO/KO;SMN2tg/0;PLS3tg/0 (SMA-PLS3het) 
and SmnKO/KO;SMN2tg/0;PLS3tg/tg (SMA-PLS3hom) mice as well as HET-PLS3het and HET-
PLS3hom mice as shown in Figure 10, and animals were genotyped as described in 4.1.3. 
 
Figure 10: Breeding scheme: Generation of SMA, SMA-PLS3het, SMA-PLS3hom, HET, HET-PLS3het and 
HET-PLS3hom genotypes. 
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4.1.3 Tagging and genotyping 
Offspring of a breeding was weaned 3 weeks after birth and animals were separated by sex. 
To allow accurate animal management each animal was tagged with a numbered ear tag. 
For genotyping purposes a biopsy of the tail tip was taken (approx. 3 mm) according to the 
German laws for animal welfare (TierSchG §6). Oligonucleotides and genotyping conditions 
are listed in 3.9.1. 
4.1.4 Timed breeding 
The generation of MEFs (4.2.1) and MNs (4.2.2) requires precise knowledge about the 
developmental stage of the analyzed embryo. For this purpose controlled timed matings 
were performed. Two nonpregnant females were mated with one male (o. n). The following 
morning females were surveyed for the presence of a vaginal plug indicative of copulation 
during the night. Vaginal plugs are remnants of the male ejaculate that can be present up to 
24 hours after mating. Positively tested females were isolated and were considered to carry 
embryos at the stage of 0.5 dpc assuming fecundation in the middle of the night. 
4.1.5 Isolation of prenatal mouse embryos 
Mouse embryos were prepared following a timed breeding (4.1.4). The pregnant mother was 
sacrificed at the desired developmental stage by CO2 gas. The uterus harboring embryos 
was fully transferred to PBS. Embryos were prepared from the uterus and the head was 
removed for genotyping purposes. Isolated embryos were either used for the isolation and 
generation of MEFs (4.2.1) or MNs (4.2.2). 
4.1.6 Subcutaneous injection of ASOs 
The SMN-ASO and Ctrl-ASO (IONIS Pharmaceuticals, (Hua et al. 2011)) were diluted in 
sterile PBS, and the concentration of 10 mg/mL (working solution) was calculated with 
photometric density (AD260). The subcutaneous injections (10–50 mg) were performed on 
postnatal days 2 and 3 (P2 and P3) with a MICROLITER Syringe (Hamilton) as reported 
(Hua et al. 2011). All pups of each litter were double blindly injected. 
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4.1.7 Righting reflex and tube test 
The righting reflex test is a method to examine muscle strength. For this test, animals were 
placed on their back on a flat surface. The time to reposition themselves was measured over 
a 30 sec period. The righting times were related to a score in the following manner: 
< 1 sec = 0, 1 – 2 sec = 1, 3 – 4 sec = 2, 5 – 6 sec = 3, 7 – 8 sec = 4, 9 – 10 sec = 5, 
> 10 sec = 6 (El-Khodor et al. 2008). Via the tube test, the proximal hind limb muscle 
strength, weakness, and fatigue in neonates was assessed. The test is performed in two 
consecutive trials, in which the animal is placed head down into a 50 mL Falcon tube so that 
the animal hangs by its hind limbs (Figure 11). Then, the hind limb score (HLS) is evaluated 
on the basis of the positioning of the hind limbs toward each other (El-Khodor et al. 2008). 
 
Figure 11: Tube test (El-Khodor et al. 2008): Hind limb scores (HLS) and respective leg positions for motoric 
ability assessment 
4.1.8 Grip strength test 
The Grip Strength Meter (TSE Systems) is a system for determining the gripping strength of 
small laboratory animals (such as rats and mice). The animal pulls a special height-
adjustable grip (with two paws) that is mounted on a high-precision force sensor, and muscle 
force is recorded in pounds (Passini et al. 2010). The grip strength test was performed at 
P36 and P108. 
4.2 EUKARYOTIC CELL CULTURE 
All cell culture procedures were performed under sterile conditions using a laminar flow 
workbench. To prevent contamination with bacteria or fungi the growth medium was 
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complemented with penicillin, streptomycin and amphotericin B unless noted otherwise. 
Eukaryotic cells were grown in sterile incubators at 37°C, 5% CO2 and 95% relative humidity. 
4.2.1 Generation of murine embryonic fibroblasts (MEFs) 
MEFs were isolated from 13.5 dpc mouse embryos. Mice of the desired genotype were 
cross-bred in a timed breeding (4.1.4) to determine the progression of pregnancy. Pregnant 
female mice were sacrificed by CO2 gas and embryos were prepared from the uterus under 
sterile conditions and washed in PBS. Visible organs like heart and liver were removed from 
the embryos. The heads were used for the isolation of DNA (4.3.1.3) for genotyping 
purposes. The embryo was ground in a 70 μm nylon cell filter using a plunger of a 20 mL 
syringe. The ground material was flushed through the cell filter with 25 mL of cell culture 
medium freshly complemented with antibiotics. Cells were pelleted by spinning for 5 min at 
1200 rpm. Cells were resuspended in 6 mL of culture medium and plated into a 6 cm tissue 
culture plate. After 24 h cells were three times carefully washed in PBS to remove cellular 
debris. Cells were expanded while providing fresh culture medium daily. This protocol was 
adapted from (Ackermann et al. 2013). 
4.2.2 Generation of murine embryonic motor neurons (MNs) 
MNs were isolated from 13 dpc mouse embryos. Mice of the desired genotype were cross-
bred in a timed breeding (4.1.4) to determine the progression of pregnancy. Pregnant female 
mice were sacrificed by CO2 gas and embryos were prepared from the uterus under sterile 
conditions and washed in PBS on ice. Coverslips in 12-well plates were coated with poly-D-
lysine in PBS (1:100) for one hour. After the incubation time, cover slips needed to be 
washed three times in sterile PBS and left to dry. Then they were coated with laminin. 700 µL 
PBS was put in eppendorf tubes for collecting spinal cords from mouse embryos after they 
had been isolated from them. Therefore, embryos needed to be fixed with four minutien pins 
on silgard dishes filled with PBS. The heads were cut off in advanced and used for the 
isolation of DNA (4.3.1.3) for genotyping purposes. Embryos were fixed with their back in 
upside position. First, the skin was gently torn away on the back of the embryo, then the 
spinal cord (s. c.) was removed by cutting with minutien pins on each side of the spine. 
Afterwards, fine science forceps were slid under to carefully loosen the s. c.. The 
surrounding meninges including ganglia cells were removed as completely as possible. The 
collected s. c. were stored in PBS on ice for some time until the isolation of all s. c. was 
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finished. All further steps were carried out under the sterile hood. The s. c. were centrifuged 
for 10 min at 1000 x g and 4°C. Afterwards the supernatant was removed and discarded. In 
the meanwhile a trypsin solution (1:20) was prepared. 500 µL of this solution was added to 
each tube, samples were mixed and centrifuged for 10 min at 1000 x g and 4°C. During that 
time the plating medium was prepared and sterile filtered (50 mL: 45.5 mL DMEM, 2.5 mL 
FBS, 1.5 mL 20% glucose, 0.25 mL penicillin, 0.25 mL streptomycin, 0.5 mL amphotericin 
B). The trypsin was pipetted off and the trypsinization reaction was stopped with 500 µL 
plating medium containing DNAse I (1:20). Spinal cords were resuspended with by very 
carefully pipetting up and down. Then more plating medium was added to adjust the volume. 
Tubes were left for 2 min for bigger debris to stay at the bottom. The upper fraction was 
taken of the solution without touching the tube’s bottom with the tip and transferred to interim 
plates for 30 min. Afterwards, the cell suspension was taken to a tube, cells were counted 
(70.000 cells/cover slip) and incubated o. n. at 37°C. On the next day, the medium was 
changed to Neurobals Medium (10 mL: 200 µL B27, 20% glucose, 200 µL horse serum, 
10 µL mGDNF, 10 µL hBDNF, 10 µL rCNTF). Cells were cultured for 7 days. This protocol 
was adapted from (Oprea et al. 2008). 
4.2.3 Cultivation of eukaryotic cells 
Murine embryonic fibroblasts (MEFs) were cultivated in DMEM (Dulbeccos’s Modified Eagle 
Medium) complemented with 10% fetal bovine serum. Routinely, cells were cultivated in 
75 cm² or 25 cm² tissue culture flasks and split into new flasks when reaching confluence 
state. Cells were washed with 1x PBS without Mg2+ and Ca2+ and trypsinized using Trypsin-
EDTA until cells detached from the surface. Trypsinization was stopped with at least 1 
volume of culture medium. The cell suspension was homogenized and evenly distributed to 
new tissue culture flasks. Depending on the proliferation rate cells were distributed at 
different density. In general, MEFs were split 1:5. MNs were cultivated in plating medium o. 
n. (first day after isolation) and Neurobasal medium (+B27, +20% glucose) from the second 
day on as described in section 4.2.2. MNs were never cultured for longer time periods. 
Therefore no cell splitting was necessary. They were always harvested after one week for 
further experiments. 
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4.2.4 Counting cells using a Neubauer cytometer 
Some applications required defined cell numbers and growth densities to work optimally. To 
determine the number of cells in a suspension, a Neubauer counting chamber was used. 
After trypsinization of cells (4.2.1) cells were well homogenized in excess of culture medium. 
30 μL of the homogenized suspension were applied to the counting chamber. Under a 
standard microscope the cell number was determined in 4 quadrants of the counting 
chamber and the mean was calculated. The cell concentration in the cell suspension is mean 
of determined cells in 4 quadrants x 104 cells/ml. 
4.2.5 Treatment of cells with FITC-Dextran 
MEFs were plated cover slips in 12-well plates (100.000 cells/well) in 1 mL normal DMEM 
growth medium and kept o. n. to attach and grow. At the next day a 10x FITC-dextran stock 
solution (50 mg/mL) was prepared in sterile PBS. Then the growth medium was removed 
from the cells. To each well 500 µL of starvation medium was added (DMEM transparent, 
+2% FBS). MEFs were incubated for 10 min at 37°C. During the incubation time 1x FITC-
dextran working solution was prepared (5 mg/mL) in starvation medium. The starvation 
medium was removed from the cells and 500 µL of 1x FITC-dextran was added per well. 
MEFs had been incubated for 0, 10 and 20 min at 37°C (in tripletts). Afterwards the solution 
was removed and the cells were placed on ice and washed three times with icecold PBS. 
Phalloidin was added to each well and incubated for one hour at room temperature (RT), 
then washed three times with PBS and stained with Hoechst (3 min). Finally, MEFs were 
washed again three times with PBS, rinsed in sterile water and mounted in Mowiol. 
4.2.6 Immunostaining procedures for MNs 
Cover slips with cultured MNs upon were fixed with 4% PFA for 15 min after being transfered 
to a new 12-well plate. Next, they were washed three times with PBS for 5 min. In the 
following step they were permeabilized in PBS containing 0.2% Triton X-100 for 5 min and 
then blocked in PBS containing 5% BSA and 5% horse serum for approx. one hour, followed 
by the incubation with the first antibody (o. n.) in PBS containing 5% BSA and 5% horse 
serum (-ChAT, -NF: both 1:100 (Table 9)). On the next day, the MNs were washed three 
times for 10 min with PBS and afterwards incubated with the secondary antibody (two hours) 
in PBS containing 5% BSA (α-goat IgG Alexa fluor 568, α-rabbit IgG Alexa fluor 488: both 
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1:500 (Table 10)). Again the cells needed to be washed three times for 10 min with PBS and 
afterwards stained with Hoechst (3 min). Finally, MNs were washed for 5 min in PBS, rinsed 
in sterile water and mounted in Mowiol. 
4.2.7 Cryoconservation of cells 
Confluent cell layers were detached from the surface by trypsinization (4.2.1). Cells were 
pelleted by centrifugation at 200 x g for 5 min and resuspended in cryo-medium containing 
DMSO as a cryoprotective agent. For MEFs a cryomedium containing 10% DMSO in FBS 
was applicable. Cells from a growth area of 25 cm² were resuspended in 1 ml of cryo-
medium and transferred to a cryo-tube. These were frozen to -80°C using an isopropanol-
based freezing aid which allowed controlled cool down rates of approx. 1°C/min. For long 
term storage cells were transferred to liquid nitrogen storage. To take back frozen cells to 
culture, the frozen cryo-tube was quickly thawed in a 37°C water bath. The thawed cell 
suspension was transferred to pre-warmed culture medium and immediately plated to a 
25 cm² tissue culture flask. 
4.3 MOLECULAR BIOLOGY METHODS 
4.3.1 Isolation of DNA 
In the following chapter different methods of DNA purification will be explained. All methods 
vary in the obtained purity of DNA and the method of DNA isolation was chosen according 
to the downstream application. All isolated DNAs were stored at -20°C. 
4.3.1.1 Isolation of genomic DNA from murine tail biopsies 
A single tail biopsy sample was lysed in 493 μL tissue lysis buffer (3.5) complemented with 
7 μL Proteinase K (200 μg/mL) at 55°C in a shaking heating block at approx. 900 rpm. Hair 
and insoluble debris were removed by 10 min centrifugation at 13200 rpm. The supernatant 
was mixed with 500 μL isopropanol in a new reaction tube to precipitate the DNA. 
Precipitation was continued for 2 min at RT. DNA was pelleted for 10 min at 13200 rpm and 
washed with 500 μL of EtOH. After centrifugation for 5 min at 13200 rpm the EtOH was 
discarded and the DNA was dried in a 37°C heated cabinet or in the Concentrator device. 
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At last the pellet was resuspended in 100 μL TE-4 (3.5) containing 50 μg/mL RNase A to 
degrade possible RNA contamination. 
4.3.1.2 Isolation of genomic DNA from tissues 
To obtain DNA of good purity from cells and animal tissues the gDNA Blood & Tissue kit 
(Qiagen) was used according to the manufacturer’s instructions. For routine use, genomic 
DNA from pelleted cells and small amounts of tissue was isolated as previously described 
for tail biopsies (4.3.1.1). Depending on the tissue size the lysis step was increased in length. 
To improve DNA purity the lysate was optionally subjected to phenol-chloroform extraction 
(4.3.1.3). 
4.3.1.3 Isolation of genomic DNA from tissues (Phenol-Chloroform) 
Following tissue lysis in lysis buffer with proteinase K cellular debris was pelleted for 20 min 
at 13200 rpm. To minimize material loss during phenol-chloroform extraction a gel-based 
phase separating system was employed. Phase Lock Gel Heavy (5 Prime) tubes were 
prepared by spinning 1 min at 13200 rpm. The cleared lysate was transferred to the Phase 
Lock tube. 1 volume phenol-chloroform was added (i.e. ½ vol. phenol + ½ vol. 
chloroform/isoamylalcohol (24:1) and mixed by vortexing. The Phase Lock tube was rotated 
for 5 min and then spun for 5 min at 13200 rpm. The upper aqueous phase was transferred 
to a fresh Phase Lock tube and previous steps were repeated with 1 vol. of phenol-
chloroform. The procedure was finally repeated with 1 vol. of pure 
chloroform/isoamylalcohol. After centrifugation the aqueous phase was mixed with 3 
volumes of ice cold 100% EtOH and 0.1 vol. of 3M NaAc (pH 5.2). DNA was precipitated o. 
n. at -20°C and afterwards pelleted for 20 min at 13200 rpm. DNA was washed in 70% EtOH 
and repeatedly centrifuged. After drying in a heating cabinet, the pellet was resuspended in 
TE-4 with 50 μg/mL RNase A. 
4.3.1.4 Isolation of genomic DNA concentration via spectrometry 
Concentrations of DNA solutions were determined using a NanoDrop ND-1000 
spectrophotometer (Peqlab). From the measured absorption at the wavelengths of 260 nm 
and 280 nm the software calculated the DNA concentration and determined the 
260 nm/280 nm ratio which is an indicator for DNA purity. A value of 1.8 is indicative of high 
purity. Lower values point to possible remnants of ethanol, while higher values indicate the 
presence of RNA. 
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4.3.2 Isolation of RNA 
RNA was handled under RNase-free conditions including appropriately treated reaction 
tubes and stuffed pipette tips. RNA in aqueous solution was always kept on ice and was 
stored at -80°C. 
4.3.2.1 Isolation of RNA from tissues 
Isolation of RNA from liver and s. c. was performed using the RNeasy Mini Kit (Qiagen) and 
QiaShredder (Qiagen) according to the manufacturer’s instructions. To ensure optimal 
breakup of organ tissue, specimens were homogenized using a rotor-stator homogenizer 
(Ultra Turrax, IKA) before proceeding with the RNA extraction. The on-column RNase-free 
DNAse digestion was performed in all RNA isolations to prevent contamination with genomic 
DNA interfering with downstream applications. RNA was eluted in RNase-free ddH2O. 
4.3.2.2 Determination of RNA concentration via spectrophotometry 
Concentrations of RNA solutions were initially determined using a NanoDrop ND-1000 
spectrophotometer (Peqlab). From the measured absorption at the wavelengths of 260 nm 
and 280 nm the software calculated the RNA concentration and determined the 
260 nm/280 nm ratio which is an indicator for RNA purity. A value of 2.0 is indicative of high 
purity. The determination of RNA concentrations with a standard spectrophotometer is 
insufficiently precise to allow reliable quantification of transcripts via real-time PCR. For 
quantitative downstream applications RNA concentrations need to be determined more 
accurately (4.3.2.3). 
4.3.2.3 Determination of RNA concentration (Ribo-Green method) 
Accurate determination of RNA concentrations was performed using the Quant-IT 
RiboGreen RNA assay (Life Technologies) as described in the manufacturer’s instructions. 
This technique is based on the RiboGreen dye, which increases its fluorescence when 
bound to RNA. This allows RNA quantification that is unbiased by compounds absorbing at 
similar wavelengths. The assay was carried out in dark 96-well plates (#655076, Greiner) 
on a Safire² microplate reader (Tecan). RiboGreen allows absolute RNA quantification using 
an included RNA standard series ranging from 0 to 100 ng/μL. Therefore, the measured 
samples were prediluted to match the standard range. By fluorescence measurement of the 
standard series a standard curve was established by linear regression. The linear equation 
was used to determine absolute concentrations from fluorescence values obtained from 
samples. 
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4.3.3 Polymerase chain reaction 
The polymerase chain reaction (PCR) was developed by Kary Banks Mullis in 1983 (Mullis 
KB 1986). PCR utilizes thermostable DNA polymerases to extend 3’-OH ends of DNA 
oligonucleotides specifically binding to a DNA matrix molecule. Primer extension leads to 
cyclic amplification of the template, as each extension product serves as a new template in 
the subsequent cycle. In this study PCR was a fundamental tool that many applications were 
based on. PCR was used for the genotyping of mice and for the quantification of transcripts 
from single stranded cDNA. 
4.3.3.1 The standard PCR 
For standard PCR, as applied for genotyping purposes the OneTaq® Quick-Load 2X Master 
Mix with Std.-Buffer (New England Biolabs) was used. A typical PCR setup on a 25 μL scale 
is shown in Table 15. 
Table 15: Typical PCR setup: PCRs using the OneTaq® Quick-Load 2X Master Mix with Std.-Buffer (New 
England Biolabs) were routinely performed in a 25 μL scale. 
component amount 
H2O (ad 25 μL) 4.5 μL 
fwd oligonucleotide (10 μM) 3 μL 
rev1 oligonucleotide (10 μM) 2 μL 
rev2 oligonucleotide (10 μM) 2 μL 
OneTaq® Quick-Load 12.5 μL 
template (2 – 200 ng) 1 μL 
 
A starting point to assess performance of a PCR included MgCl2 concentrations of 1.5 mM 
and primer concentrations of 0.4 μM. Amplification of targets that were difficult to amplify or 
that yielded unspecific products was enhanced by adaption of PCR conditions. Increasing 
the MgCl2 concentration boosts polymerase performance on cost of primer binding 
specificity. Decreasing the MgCl2 concentration can make primer binding very specific, but 
the amplification reaction might become very ineffective. Similar effects can be achieved by 
adjustment of the annealing temperature. Low temperatures cause primers to effectively 
bind the template but allow unspecific primer binding. High temperatures increase binding 
specificity but might also reduce the number of primers binding the template, thus 
decreasing PCR efficiency. The annealing temperature of a PCR program should be 
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adjusted according to the oligonucleotide properties. Melting temperatures of 
oligonucleotides were calculated using the OligoCalc web application as listed in 3.10.2. A 
typical PCR program is shown in Table 16. 
Table 16: Standard PCR program: The usual PCR begins with an initial denaturation step melting the double 
stranded DNA template followed by 38 cycles of denaturation, annealing and extension. Finally, incomplete 
product are complemented for 10 min at 72°C. The annealing temperature varies between PCRs and depends 
on the oligonucleotide properties. The extension temperature is chosen according to the enzymes optimum 
temperature (i.e. 72°C for Taq polymerase) which may vary between enzymes. Extension time depends on 
the amplicon length and processing speed of the polymerase. 
initial denaturation 5 min 95°C  
denaturation 30 sec 95°C  
40 cycles annealing 30 sec 50 – 68°C 
extension ~1 min/kb 72°C 
final extension 10 min 72°C  
 
4.3.3.2 Reverse Transcription 
cDNA synthesis was performed using the QuantiTect Reverse Transcription kit (Qiagen) 
according to the manufacturers instructions. For quantitative real-time PCR the QuantiTect 
kit (Qiagen) was used exclusively. Prior to cDNA synthesis the RNA concentration was 
determined by the RiboGreen method (4.3.2.3). For quantitative real-time PCR 150 ng of 
RNA was reversely transcribed in a 10 μL setup. For generation of a standard series 600 ng 
of RNA was used in 20 μL. 
4.3.3.3 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) overcomes the limitations of semi-quantitative RT-
PCRs. Even though it underlies the same reaction kinetics as any other PCR, template 
amounts can be robustly determined. In contrast to the semi-quantitative PCR, qPCR 
measures product amplification as it happens during exponential phase. In this study qPCRs 
were performed on the Roche Light Cycler 1.5 using the Light Cycler Fast Start DNA Master 
SYBR green I kit (Roche) according to the manufacturer’s instructions. The SYBRgreen I 
dye preferentially binds to DNA but also to RNA. Its absorption maximum is at 494 nm (blue). 
When excited SYBRgreen emits green light (521 nm). The fluorescence is strongest when 
bound to double stranded DNA but is much weaker when bound to single stranded DNA or 
RNA. After each primer extension step of a qPCR, SYBRgreen fluorescence is measured 
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at 80°C. At this temperature double stranded DNA caused by primer dimmers or cDNA 
hairpins is denatured but longer PCR products are stable allowing a precise determination 
of PCR product amounts in every PCR cycle. As SYBRgreen binds double stranded DNA 
independently of the sequence, all PCR products including unspecific side products are 
measured. Therefore, specific product amplification is vital for SYBRgreen-based systems. 
Product specificity was surveyed by dissociation curve analysis and subsequent agarose 
gel electrophoresis. All qPCR primers used in this study amplify their target specifically at 
the indicated conditions (3.9.2). For use as a template for qPCR, cDNA was produced as 
described in 4.3.3.2. The template solution was generated by diluting cDNA 1:5 in TE-4 buffer 
(e.g 8 μL of cDNA (from 150 ng RNA in 10 μL) + 32 μL of TE-4). A standard series was 
generated from a 600 ng RNA reverse transcription reaction as shown in Table 17. 
Table 17: Dilution of a cDNA standard series for qPCR: cDNA was diluted 1:2.5 in TE-4 buffer to generate 
templates with different concentrations ranging from 64 (i.e. 64/64) to 1 (i.e. 1/64 of the starting cDNA 
concentration) 
Standard sample cDNA diluent 
standard 64 (1:2.5) 16 µL cDNA (from 600 ng RNA in 
20 µL) 
24 µL TE-4 
standard 32 (1:5) 20 µL standard 64 20 µL TE-4 
standard 16 (1:10) 20 µL standard 32 20 µL TE-4 
standard 8 (1:20) 20 µL standard 16 20 µL TE-4 
standard 4 (1:40) 20 µL standard 8 20 µL TE-4 
standard 2 (1:80) 20 µL standard 4 20 µL TE-4 
standard 1 (1:160) 20 µL standard 2 20 µL TE-4 
 
The cycle threshold of each standard concentration was plotted against the concentraton 
(log) and the standard curve was extrapolated by linear regression. This curve was then 
reversely used to calculate the concentrations of samples from their respective cycle 
threshold value. Samples were measured as duplicates and averaged using the arithmetic 
mean. For a 10 μL qPCR setup 3 μL of template solution were used. The composition of a 
typical qPCR is shown in Table 18. 
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Table 18: Typical qPCR setup for the Roche LightCycler 1.5.: qPCRs in Roche Light Cycler 1.5 using the 
SYBRgreen I Master Mix were performed in a 10 μL scale. H2O, MgCl2 solution, SYBRgreen Master Mix and 
Fast Start enzyme were provided in the kit. A MgCl2 concentration of 3 mM was suitable for all applications. 
component amount 
H2O (ad 10 µL) 2.8 µL 
MgCl2 (25 mM) 1.2 µL (3 mM) 
fwd oligonucleotide (10 µM) 1 µL 
rev oligonucleotide (10 µM) 1 µL 
SYBRgreen Master Mix 0.833 µL 
LC Fast Start Enzyme 0.166 µL 
diluted cDNA template 3 µL 
4.3.4 Agarose gel electrophoresis 
DNA fragments of different sizes were separated by agarose gel-electrophoresis for 
analytical purposes. Different concentrations of agarose (e.g. 1% – 2%) were used 
according to the size of DNA fragments to analyze. Before loading, the gel was chilled to 
4°C to become fully solid. For preparation agarose was melted in TBE buffer and 
supplemented with ethidium bromide (1:10,000). This allowed visualization of DNA when 
exposed to UV-light. DNA samples were transferred to the gel and separated at 100 to 125 
Volts depending on the gel size and agarose concentration. Results were documented using 
the ChemiDoc XRS documentation system (BioRAD). 
4.4 PROTEINBIOCHEMISTRY 
4.4.1 Extraction of proteins 
Proteins were generally isolated in RIPA buffer (Sigma-Aldrich) containing a mix of 
protease inhibitors (Complete Mini Protease Inhibitors, Roche). One tablet of protease 
inhibitors was resolved in 10 mL of RIPA buffer. All isolation steps were carried out at 4°C 
and proteins were stored at -80°C. 
4.4.1.1 Extraction of proteins from tissues 
Lysis and protein extraction from animal tissues requires additional steps for efficient tissue 
break up and lysis. To obtain protein from organs (e.g. brain, liver, lung, spinal cord or TVA 
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muscle) the tissue was homogenized in RIPA buffer containing protease inhibitors using a 
homogenizer (Precellys 24, Peqlab, program 4). Depending on tissue size 200 to 400 μL of 
RIPA buffer was used. Tissues with high protein content (e.g. brain) generally required a 
larger lysis volume. For effective lysis the homogenate was incubated on ice for 10 min. 
Next, the samples were centrifuged for 20 min at 13200 rpm and 4°C to remove cell debris 
and the supernatant was transferred to new Eppendorf tubes. For further homogenation, the 
lysates were put into a ultrasonic bath for additional 5 min. Afterwards the samples were 
again centrifuged for 20 min at 13200 rpm and 4°C and transferred to new Eppendorf tubes. 
Isolated proteins were snap-frozen in liquid nitrogen and stored at -80°C. 
4.4.1.2 Determination of protein concentration via Bradford protein assay 
Protein concentrations were determined using the protein assay according to Bradford 
(Compton and Jones 1985). The Bradford reagent contains the dye Coomassie-Brilliant-
Blue G-250, which forms complexes with cationic and nonpolar amino acids in acidic 
environment. This stabilizes the dye in its non protonated form which causes a shift of light 
absorbance maximum from 470 to 595 nm. 1 μL of protein lysate was mixed with 499 μL of 
Bradford reagent (Applichem) and incubated at room temperature for 10 min. The 
concentration was determined by measuring the absorption at 595 nm on a standard 
spectrophotometer (Eppendorf) using a standard of 0.5 to 5.0 μg of BSA for calibration. 
4.4.2 Discontinuous SDS-Page 
During SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel-electrophoresis) proteins 
are resolved according to their molecular weight within an electric field. Proteins of different 
size or molecular weight proceed through the polyacrylamide gel with different velocities. 
Furthermore, the anionic detergent SDS is applied which adapts the mass to charge ratio of 
proteins. Proteins become negatively charged and their speed in the gel is almost 
exclusively determined by their mass. SDS also denatures secondary and tertiary structures. 
Thus proteins of similar mass proceed towards the anode at same velocities without being 
impaired by their innate conformation. Hydrogen- and disulfide-bonds are severed due to 
boiling in presence of reducing compounds like dithiothreitol or β-Mercaptoethanol (Laemmli 
1970). In this study discontinuous SDS-PAGEs were carried out with 4% stacking gel and a 
12% resolving gel used to separate most target proteins. Discontinuous SDS-PAGE allows 
proteins to focus in a sharp band within the stacking gel and to simultaneously start resolving 
in the resolving gel. This effect is based on a discontinuous buffer system with low pH of 6.8 
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in the stacking gel and higher pH of 8.8 in the resolving gel. Proteins traveling through the 
stacking gel have the same charge and their speed is hardly biased by their size, as the gel 
matrix is insufficiently dense (4%). In the stacking gel proteins are focused between two ion 
fronts: The quickly moving Cl- and the slowly moving glycine which has its isoelectric point 
pI at 5.97 and therefore close to pH 6.8. As the ion front approaches the resolving gel 
(pH 8.8) glycin overtakes the proteins which are then no longer focused and resolve 
according to their size caused by interaction effects with the dense gel matrix. SDS gels 
were prepared between two vertical glass plates. First, the resolving gel (3.5) was prepared 
and isopropanol was pipetted on top to produce a sharp edge. After polymerization was 
complete, isopropanol was removed and the stacking gel (3.5) was poured on top. The total 
protein concentration of lysates was determined according to Bradford (4.4.1.2). 10 to 20 μg 
of total protein were supplemented with 1 volume of 2x SDS sample buffer and boiled for 5 
min before being loaded onto the gel. As a protein ladder 10 μL of the PageRuler™ 
Prestained Protein Ladder (Thermo) were loaded. Electrophoresis was performed at low 
initial voltage of 80 Volts while proteins were moving through the stacking gel. Voltage was 
increased up to 180 Volts while resolving. 
4.4.3 Transfer of proteins to PVDF blotting membranes 
Proteins that have been resolved by SDS-PAGE (4.4.2) were electrophoretically transferred 
to PVDF (polyvinylidene fluoride) blotting-membranes. All transfers have been performed 
via wet-blot (tank–blot) according to Towbin (Towbin et al. 1979). Protein transfer was 
carried out at 4°C for 2 h at 100 Volts or over night at 30 Volts. Successful transfer of proteins 
could be recognized due to pre-stained protein ladders that were visible on the blotting 
membrane. 
4.4.4 Immunostaining of proteins on PVDF membranes 
The immunoblot or Western Blot utilizes antibodies to specifically detect proteins. Primary 
antibodies specifically bind epitopes of the target protein. The primary antibody is then 
detected by secondary antibodies which are conjugated to HRP (horseradish peroxidase). 
The desired protein can finally be detected by chemiluminescence using Super Signal West 
Pico ECL Substrate (Thermo). This substrate contains H2O2 and luminol. As HRP cleaves 
H2O2, luminol will luminesce. After blotting (4.4.3) the membrane was shortly washed in 
TBST and blocked with 6% milk powder in TBST at 4°C for 2 h or o. n.. Primary antibodies 
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were applied in TBST with 2% milk powder and incubated at 4°C. Concentration and the 
duration of incubation time for each antibody are stated in 3.8.1. The membrane was washed 
5 times for 5 min in TBST to remove non-bound antibodies. The secondary antibody was 
applied in TBST with 2% milk powder at concentrations indicated in 3.8.2. All secondary 
antibodies used for immunoblots were HRP-conjugates. To remove non-bound secondary 
antibody the membrane was washed 5 times for 5 min in TBST. To visualize the protein of 
interest the membrane was incubated for 5 min in chemiluminiscence substrate. Results 
were recorded using the ChemiDoc XRS system (BioRAD). Densitometric analysis was 
performed using the QuantityOne Software (BioRAD) or ImageJ (3.10.1). 
4.4.5 Restoring of PVDF membranes for re-blotting 
For repeated immunological detection of proteins on previously used PVDF membranes 
bound antibodies were removed by shaking the membrane for 7 to 15 min in Restore 
Western Blot Stripping Buffer (Thermo). Afterwards, the membrane was washed twice in 
TBST before proceeding with a new immunostaining. 
4.5 HISTOLOGICAL METHODS 
In this study hearts, intestine, lung, TVA muscle and s. c. of SMA, SMA-PLS3het, SMA-
PLS3hom, HET, HET-PLS3het, HET-PLS3hom and WT mice were histologically analyzed 
at various developmental stages. 
4.5.1 Histological preparation of animal tissues 
4.5.1.1 Paraffin-embedding of mouse tissues 
Hearts, lungs and intestines were isolated from mice at P21. Preparation of the specimen 
for micro-dissection included fully automated dehydration and paraffin embedding using a 
tissue processor (TP1028, Leica). After micro-dissection, paraffin sections were flattened in 
a water bath and dried o. n. at 37°C. The following Haematoxylin/Eosin staining is described 
in section 4.5.2. 
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4.5.1.2 Cryo-embedding of mouse tissues 
For proprioceptive input staining, the spinal cords of P21 mice were dissected from 
euthanized mice and fixed in 4% paraformaldehyde (PFA)/PBS for 1 day. The lumbar 
L4 – L5 region was quickly rinsed in PBS, embedded in tissue-freezing medium (Jung) after 
cryoprotection (first day – 20% sucrose; second day – 30% sucrose) and sliced into 40-mm-
thick sections (cryostat, Leica). The following immunostaining is described in section 4.5.3. 
4.5.2 Haematoxylin/Eosin staining of paraffin-embedded slices 
HE staining (haematoxylin and eosin staining) was used as an initial standard staining 
procedure to allow gross histological analysis. Upon HE staining nuclei are stained dark blue 
while most parts of the cytoplasm (i.e. proteins) are stained red to pink. Paraffin-embedded 
sections were first deparaffinized for 2 x 15 min in xylene and rehydrated in a series of EtOH 
solutions of decreasing concentrations (each 2 min in 100% EtOH, 96% EtOH, and 70% 
EtOH). Sections were shortly washed in PBS and H2O. Staining with haematoxylin was 
performed for 6 min. Specimens were shortly rinsed in water and then washed for 15 min in 
fresh water. Finally, sections were shortly rinsed in ddH2O. Eosin staining was performed 
for 1 min before shortly washing in H2O. At the end specimens were dehydrated with an 
EtOH series of increasing concentration (each 1 min in 70% EtOH, 96% EtOH and 100% 
EtOH). For sample preparation sections were incubated for 1 min in xylene and mounted 
with Eukitt mounting medium. 
4.5.3 Immunostaining of NMJs from TVA and cryo-embedded spinal cord 
sections 
For NMJ staining, TVA muscle was fixed in 4% PFA for 20 min. The tissue was rinsed three 
times in PBS for 10 min so that excess PFA would be removed. From this step on, the 
staining protocol followed the procedure described below for MN staining. Primary antibody 
dilutions were mouse α-SV2 together with mouse α-NF. The secondary antibody was 
donkey α-mouse Alexa fluor 488. To outline endplates in muscle tissue, BTX conjugated 
with Rhodamine (1.5 ng/mL, Invitrogen) was used. Samples were permeabilized and 
blocked in PBS containing 4% BSA, 1% Triton X-100, and PBS for 1 h. Finally, samples 
were incubated with goat α-ChAT and rabbit α-VGLUT1 antibodies or goat α-Plexin and 
mouse α-Smi32 (o. n.). Samples were washed and incubated with secondary antibodies 
(donkey α-rabbit Alexa fluor 488 and donkey α-goat Alexa fluor 568). Samples were 
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mounted in Mowiol (Kuraray) for further analysis. All dilution and conditions for primary and 
secondary antibodies are listed in section 3.8.1 and 3.8.2. 
4.5.4 Microscopy 
Paraffin-embedded organ sections were microscopically analyzed. Images were recorded 
on a Zeiss AXIO microscope and the Zeiss M2 imaging system using the ZEN software 
(Zeiss, Jena, Germany). Routinely, whole mount overview images were taken using 1.25x 
magnification. For high resolution analysis multiple images have been taken to finally cover 
the whole sample using 10x magnification. Images were merged and blended using the 
Demo version of the Autostitch software. Overlap of image recording at the microscope 
allowed perfect panoramic assembly of single images. Images used for organ analysis that 
are shown in this work are high resolution panoramic assemblies consisting of multiple 10x 
magnification shots. Imaging of NMJs was performed with a Zeiss microscope (Axio 
Imager.M2) with the Apotome.2 system to mimic confocality together with a 40x and 63x oil 
immersion objective lens with 1.4 NA. Images of MN soma and proprioceptive inputs were 
taken with the META 510 confocal microscope (Zeiss). Z-stacks of 50 – 60 slices at a 0.5 
µm interval were created with ZEN software (Zeiss). Proprioceptive input numbers on MNs 
and MN soma size were quantified with ImageJ (Fiji) software. By creating 3D regions of 
interest (ROIs) of the selected MN soma the macro ‘CountAxonalInputsV21.ijm’ is able to 
measure the exact soma size and in addition detects and quantifies the proprioceptive inputs 
per MN. Each image was split into two channels: one for ChAT positive MN soma and 
another for VGlut1 positive inputs and ensured that voxels were isometric. Subsequently, 
both single-channel images were smoothed: in the MN soma image each pixel was replaced 
with the median of its 6x6x4 neighborhood and an optional automatic background removal 
was performed by Li’s Minimum Cross Entropy thresholding method (Li and Tam 1998). In 
the VGlut1 positive image each pixel was replaced with the median of its 16x16x16 
neighborhood. In the smoothed VGlut1 positive image the inputs were automatically 
segmented using the 3D simple segmentation function of the 3D ImageJ Suite (Ollion et al. 
2013) under the following criteria: the intensity threshold was obtained from Otsu's threshold 
clustering algorithm applied to the stack histogram (Otsu 1979) and 20 voxel were used as 
a minimum size criterion. In smoothed ChAT positive images the experimenter draws the 
smallest possible cuboids around non-overlapping MN soma. Within the cuboid further 
segmentation was performed automatically using the Otsu method to obtain input values for 
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a 3D hysteresis thresholding (3D ImageJ suite). The resulting mask was dilated by 4 voxels 
and finally holes in the mask were filled. Once all suitable MN somas within an image were 
selected, the macro processed each 3D selection, again using functions of the 3D ImageJ 
suite, so that it first quantified all VGlut1 inputs within the selection and then calculated only 
those relevant for a given MN soma within 2 µm distance. Additionally, the area of each MN 
soma was determined. More detailed functions and information of the macro are given in 
the appendix. All experiments were double blinded. 
4.6 ELECTROPHYSIOLOGICAL ANALYSES (PERFORMED BY DR. LAURA 
TORRES BENITO) 
4.6.1 FM1-43 Endocytosis Experiments 
TVA was dissected in HBSS solution (14025, GIBCO) and afterwards incubated for 20 min 
in external physiological solution containing the following (mM): 145 NaCl, 5 KCl, 10 HEPES, 
2 CaCl2, 1 MgCl2, and 10 glucose. The N. intercostalis innervating the TVA muscle was 
stimulated via a suction electrode pulled from borosilicate glass tubes and mounted in a 
bipolar electrode holder connected to a universal stimulus isolator and a universal digital 
stimulator. Contraction of the muscles upon nerve stimulation was checked visually under 
the microscope. After incubation with 3 mM FM1-43, we applied a current pulse train either 
at 20 Hz or 5 Hz for 1 s (1 mA amplitude, 0.5 ms pulse duration) to load the endocyted 
synaptic vesicles. Subsequently, we washed muscles with external solution that did not 
contain CaCl2 or 3 mM MgCl2 but did contain ADVASEP-7 to efficiently remove the non-
internalized FM1-43, and we fixed the muscles with 4% PFA. We also incubated TVA 
muscles with BTX- 647 (1 ng/mL; B-35450, Life Technologies) to stain postsynaptic 
terminals and easily localize the NMJs, then mounted them on slides. We used three 
animals per genotype and stimulation set. Imaging was performed as described in section 
4.5.4. All imaging processes and analyses were blinded. We analyzed images with Fiji on a 
macro setting and applied the Li threshold method to the postsynaptic terminals to delineate 
the area of interest in the presynaptic site. Because at P10 the distribution of vesicles is 
quite homogenous along the NMJ, we quantified the mean intensity of the FM1-43 dye at 
the presynaptic terminal, which excluded possible variability due to the size. 
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4.7 STATISTICAL ANALYSES 
Data obtained in this study was generally undertaken to statistical evaluation to analyze the 
technical error of a measurement or to determine the significant difference between groups 
of biological replicates. All statistical analyses were carried out using Excel 2010/2013 
(Microsoft) and GraphPad Prism (GraphPad Software). Some measurements were 
recorded as duplicates (e.g. qRT-PCR, Light Cycler 1.5, n = 2) or triplicates (RiboGreen 
method of determining the RNA concentration, n = 3) to allow calculation of the mean to 
minimize the technical error caused by device inaccuracies or inaccurate pipetting. To 
assess biologically significant differences, groups of biological replicates (e.g. mice, organs 
or cells of a specific genotype) were compared to each other. N gives the number of 
biological replicates; i.e. the number of individuals per group observed. The average of each 
group was calculated by the arithmetic mean, while the dispersion of readout values within 
a group was represented by the standard error of the mean (SEM). Error bars within bar 
charts represent the SEM unless indicated otherwise. Student’s t-Test was employed to 
determine the statistical significant difference between groups. The probabilities for data 
points belonging to different groups are 0.05 (*), 0.01 (**) or 0.001 (***). Lok-rank (Mantel-
Cox) test was performed for survival statistics. 
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5. Results 
Previous data of our laboratory have shown that ubiquitous overexpression of one PLS3 
transgenic allele in the severe Taiwanese SMA mouse model restores MN and NMJ function 
as well as motoric abilities but fails to rescue survival, most likely because of a dramatic 
multi-organ dysfunction that could not be rescued by PLS3 overexpression (Ackermann et 
al. 2013). Therefore the major aim of this study was to generate a SMN-ASO-induced milder 
SMA mouse model to confirm the beneficial impact of PLS3 as observed in humans. 
5.1 ANALYSES OF UNINJECTED SMA-PLS3HOM MICE 
First, the PLS3 transgenic allele (Ackermann et al. 2013) was crossed into the Taiwanese 
SMA mouse strain (Riessland et al. 2010). Next, a SMA mouse (SmnKO/KO;SMN2tg/0) 
overexpressing PLS3 (here named SMA-PLS3het for SmnKO/KO;SMN2tg/0;PLS3tg/0 and SMA-
PLS3hom for SmnKO/KO;SMN2tg/0;PLS3tg/tg) was generated, as well as Smn heterozygous 
mice (here named HET for SmnKO/WT;SMN2tg/0) overexpressing PLS3 (HET-PLS3het for 
SmnKO/WT;SMN2tg/0;PLS3tg/0 and HET-PLS3hom for SmnKO/WT;SMN2tg/0;PLS3tg/tg). HET 
mice were used as controls. The breeding scheme is shown in Figure 10 (Material and 
Metods: Chapter 4.1.2). To better understand whether the amount of PLS3 that is 
overexpressed in SMA mice influences the survival rate, weight progression, and motoric 
abilities in SMA mice (C57BL/6N), uninjected SMA-PLS3het and SMA-PLS3hom mice were 
compared in a first approach. This experiment was performed to verify whether homozygous 
PLS3 may act as a protective modifier and rescues the mouse phenotype including the 
survival rate in comparison to uninjected SMA and SMA-PLS3het mice (Ackermann et al. 
2013). HET-PLS3het and HET-PLS3hom mice were used as internal control groups for this 
study. 
5.1.1 Survival rate and weight progression 
The comparison of the survival rate of SMA-PLS3hom mice (12.95 ± 3.26 days) with SMA-
PLS3het mice (11.67 ± 3.78 days) showed no significant difference (Figure 12). The same 
was true for their weight progression (Figure 13). We thus concluded that elevated PLS3 
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expression alone on the severe SMA background is unable to overcome the multi-organ 
impairment found in the severe SMA mouse model (Ackermann et al. 2013). 
 
Figure 12: Kaplan-Meier curves show the survival rate of untreated SMA-PLS3het and SMA-PLS3hom 
mice. There is no significant difference in the survival between these two groups: 12.95 ± 3.26 days for SMA-
PLS3het (n = 20) and 11.67 ± 3.78 days for SMA-PLS3hom mice (n = 22). A log-rank (Mantel-Cox) test was 
used. 
 
Figure 13: Weight progression of uninjected SMA and HET mice overexpressing PLS3 on C57BL/6N 
background: SMA-PLS3het (n = 20) and SMA-PLS3hom (n = 22) mice in comparison to HET-PLS3het 
(n = 32) and HET-PLS3hom mice (n = 26). 
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5.1.2 Motoric ability 
To investigate whether the homozygous PLS3 overexpression led to any improvements 
considering the motoric functions of these severely affected SMA mice, tube and righting 
tests were performed. Unfortunately, also the motoric ability of SMA-PLS3hom vs. SMA-
PLS3het mice did not show any significant difference in the tube test (Figure 14) or in the 
righting reflex test (Figure 15). The two motoric tests were carried out as reported in section 
4.1.7. 
 
Figure 14: Tube test of SMA and HET mice overexpressing PLS3 on C57BL/6N background. SMA-
PLS3hom (n = 22) mice show no significant difference to SMA-PLS3het mice (n = 20) in performance. 
 
Figure 15: Righting reflex test of SMA and HET mice overexpressing PLS3 on C57BL/6N background. 
SMA-PLS3hom (n = 22) mice show no significant difference to SMA-PLS3het mice (n = 20) in performance. 
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These findings induced the idea to generate and establish an intermediate SMA mouse 
model which resembles more the human condition in asymptomatic SMN1-deleted 
individuals overexpressing PLS3 (Oprea et al. 2008) as the severely affected Taiwanese 
SMA mouse model is suffering from intense multi-organ dysfunction that was not rescued 
by increased PLS3 overexpression and therefore the protective role of this disease modifier 
could neither lead to a survival rescue nor to fully restored motoric abilities in SMA-PLS3hom 
mice. We therefore decided to generate a milder SMA model that reflects the human 
situation in asymptomatic discordant families in order to finally prove that PLS3 
overexpression has beneficial effects, including prolonged survival. For this, a combinatorial 
therapy of low-dose SMN antisense oligonucleotide (ASO) and PLS3 overexpression was 
applied. 
5.2 PROTEIN EXPRESSION STUDIES IN SMA-PLS3HET VS. SMA-
PLS3HOM UNINJECTED MICE 
To verify the expression of PLS3, Western blot analyses of spinal cord, brain, 
gastrocnemius, transverse abdominis, lung and skin were performed in HET-PLS3het and 
HET-PLS3hom mice. The isolation of the organs was done at P10 as described in section 
4.4.1. In all analysed tissues there was a significant increase in the PLS3 overexpression in 
HET-PLS3hom mice with spinal cord, brain and gastrocnemius having the highest increases 
(Figure 16 and Figure 17). The WB analyses were performed as described in section 4.4.2 
to 4.4.4. The PLS3 overexpression increase in HET-PLS3hom relative to expression levels 
in HET-PLS3het is as followed: spinal cord: 51.14%; brain: 47.11%; gastrocnemius: 57.37%; 
transverse abdominis: 42.92%; lung: 45.07% and skin: 38.11%. 
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Figure 16: WB analyses of PLS3 transgene expression of P10 mouse protein lysates of spinal cord, 
brain, gastrocnemius, transverse abdominis, lung and skin of uninjected HET-PLS3het and HET-PLS3hom 
mice (N = 4). V5 staining labels only PLS3 transgene. ACTB was used as a loading control. 
 
Figure 17: Quantification of PLS3 transgene expression in heterogenous and homogenous P10 mice. 
Increase of PLS3 in HET-PLS3hom relative to expression levels in HET-PLS3het mice: spinal cord.: 51.14%; 
brain: 47.11%; gastrocnaemius: 57.37%; TVA: 42.92%. lung: 45.07%; skin: 38.11%; N = 4; * p < 0.05; 
** p < 0.01; *** p < 0.001, two-tailed Student’s t test. Error bars represent SD. 
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5.3 OPTIMIZATION AND DOSAGE FINDING OF SMN-ASO INJECTION 
SMN-ASOs correct SMN2 splicing by blocking an intronic splice silencer and thus prevent 
binding of the splice factor hnRNPA1 which promotes exon 7 skipping (Rigo et al. 2012). 
Consequently, SMN-ASOs facilitate exon 7 inclusion and are stable up to 6 months. Pre-
symptomatic intracerebroventricularly (ICV) and subcutaneously (s.c.) injection of high 
doses of ASO (up to 160 µg twice) fully rescues the SMA phenotype (Hua et al. 2011). 
Accordingly, we decided to subcutaneously inject low doses of 10 – 50 µg of SMN-ASO on 
P2 and P3 in SMA mice on a congenic FVB/N background in order to produce an 
intermediate SMA mouse model. The observed survival rate varied quiet dramatically at 
each dose (Figure 18), making an efficient analysis of the modifier later one rather 
problematic. Instead, using the same injection scheme in SMA mice on a congenic 
C57BL/6N background turned out to vary by far less (Figure 19). Because 40 and 50 µg 
were shown to prolong survival too much, the analysis was restricted to SMA mice injected 
with 10, 20, and 30 µg SMN-ASO and survival was compared to that of uninjected and 
control (ctrl)-ASO-injected mice (Figure 19). Injection of 30 µg SMN-ASO on P2 and P3 was 
chosen as an adequate dosage for generating of an intermediate SMA mouse model 
surviving approximately four weeks (26 ± 9.48 days). This observation emphasizes the 
relevance of the genetic background influencing the disease phenotype. 
 
Figure 18: Optimization and dosage finding of SMN-ASO injection in SMA mice on a congenic FVB/N 
background: Kaplan-Meier curves show survival in SMA mice injected subcutaneously with 10 to 50 μg of 
SMN-ASO or 50 μg ctrl-ASO at P2 and P3. Notably is the large variability in survival in comparison to SMA 
mice of the same genotype on C57BL/6N congenic background (Figure 19). The mean age of survival was: 
59.80 ± 60.79 days, n = 20 for 10 μg; 72.58 ± 65.15 days, n = 19 for 20 μg; 102.41 ± 73.91 days, n = 35 for 
30 μg; 126.52 ± 98.58 days, n = 27 for 40 μg and 192.05 ± 97.50 days, n = 22 for 50 μg SMN-ASO in 
comparison to 14.57 ± 4.99 days, n = 21 uninjected and 11.13 ± 2.30 days, n = 8 ctrl-ASO injected mice. 
(Taken from (Hosseinibarkooie et al. 2016).) 
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Figure 19: Optimization and dosage finding of SMN-ASO injection in SMA mice on a congenic 
C57BL/6N background: Kaplan-Meier curves show the survival rate of SMA mice injected at P2 and P3 with 
different SMN-ASO doses. Uninjected: 16 ± 2.85 days, n =22. 50 µg ctrl-ASO: 14 ± 3.89 days, n = 15. 10 µg 
SMN-ASO: 21 ± 3.95 days, n = 11. 20 µg SMN-ASO: 21 ± 7.37 days, n = 8. 30 µg SMN-ASO: 26 ± 9.48 days, 
n = 22. (Taken from (Hosseinibarkooie et al. 2016).) 
Only some phenotypic analyses were carried out with mice on FVB background. These 
include: survival, weight progression, tube and righting test and showed large variability and 
too strong improvement under SMN-ASO therapy and therefore we doubted that the effect 
of PLS3 will be reliably seen. Therefore all main experiments of this study were performed 
with SMA mice on a C57BL/6N background to reliably dissect the modifying effect of PLS3. 
All pups were injected subcutaneously with 30 µg SMN-ASO at P2 and P3. 
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5.4 PLS3 OVEREXPRESSION RESCUES SURVIVAL ON A SMN-ASO 
INDUCED INTERMEDIATE SMA MOUSE MODEL 
Strikingly, more than 60% of SMA-PLS3hom mice survived >250 days, and 30% were still 
alive at >400 days (mean survival: 219 ± 176.78 days). SMAPLS3het mice showed a less 
prolonged survival (169 ± 176.11 days), reflecting a PLS3-dependent dosage effect (Figure 
20). 
 
Figure 20: Kaplan-Meier curves show the survival rate of PLS3-overexpressing or –non-
overexpressing SMA mice treated with 30 µg of SMN-ASO at P2 and P3. PLS3 overexpression drastically 
increased the survival to 169 ± 176.11 days (n = 23) for SMA-PLS3het and to 219 ± 176.78 days (n = 11) for 
SMA-PLS3hom in comparison to SMA mice without PLS3 overexpression. A log-rank (Mantel-Cox) test was 
used. The four groups of mice differ from each other highly significantly (p value < 0.001). (Taken from 
(Hosseinibarkooie et al. 2016).) 
SMA-PLS3het and SMA-PLS3hom mice developed ear and tail necrosis over time, starting 
from one month of age (Figure 21, right part), in similarity to SmnKO/KO;SMN2tg/tg mice (Hsieh-
Li et al. 2000). Additionally, these animals showed normal behaviour in feeding and 
grooming. 
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Figure 21: PLS3 overexpression improved phenotypical development in the intermediate SMA mouse 
model, similar to results for HET mice. The scale bar represents 2 cm. (Taken from (Hosseinibarkooie et al. 
2016).) 
5.5 WEIGHT PROGRESSION STUDIES 
SMA-PLS3het and SMA-PLS3hom mice on C57BL/6N background continuously gained 
weight within the observed period of time (Figure 22). Although SMA-PLS3hom mice were 
slightly heavier than SMA-PLS3het mice, they did not reach the body weight of HET mice. 
 
Figure 22: Weight progression (C57BL/6N) of SMA (uninjected, n = 22), and SMN-ASO injected SMA 
(n = 19), SMA-PLS3het (n = 10) and SMA-PLS3hom (n = 11) mice in comparison to HET (n = 18) mice 
(Modified from (Hosseinibarkooie et al. 2016)). 
In comparison to the weight progression on C57BL/6N background, the mice on FVB/N 
background lived much longer after being injected with 30 µg SMN-ASO at P2 and P3. The 
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weight progression analysis (Figure 23) showed no significant difference between SMA and 
SMA-PLS3het mice and was more similar to the control groups (HET and HET-PLS3het). 
 
Figure 23: Weight progression (FVB/N) of SMN-ASO treated SMA (n = 29), SMA-PLS3het (n = 12), HET 
(n = 26), and HET-PLS3het (n = 11) mice. 
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5.6 MOTORIC ABILITY IN THE INTERMEDIATE SMA MOUSE MODEL 
We next analyzed the impact of PLS3 overexpression in the intermediate SMN-ASO-
injected SMA mouse model by testing the motoric performance using the tube test and 
righting reflex test in neonates and the grip strength test for mice after they were separated 
from their parents. Tube test and righting reflex test were performed for both background 
strains (C57BL/6N and FVB/N) and described in the following section. Performance and 
score point criteria for both tests are listed in section 4.1.7. In C57BL/6N mice, there was no 
significant difference in tube test performance between SMA, SMA-PLS3het, SMA-
PLS3hom, and HET mice at very early postnatal time-points. In contrast, at P13 a significant 
difference between SMA and HET mice was observed and was partially rescued by 
heterozygous and homozygous PLS3 overexpression (Figure 24). Similar as observed in 
the weight progression of FVB/N mice (5.5) their ability to perform the tube test showed no 
significant differences between SMA and SMA-PLS3het and is comparable to the ones of 
HET and HET-PLS3het (Figure 25). The SMN-ASO injected FVB/N SMA mice are by far too 
healthy to be described as a real intermediate SMA mouse model. All further histological 
analyses, cell cultures and immunostainings exclusively were only done with mice on 
C57BL/6N background in order to work with an appropriate intermediate SMA phenotype. 
 
Figure 24: Tube test of neonatal SMN-ASO-injected mice (C57BL/6N) (P1 – P14). SMA-PLS3het and 
SMA-PLS3hom mice, but not SMA mice, show an improvement in performance (P12 – P14) (n ≥ 10). (Modified 
from (Hosseinibarkooie et al. 2016).) 
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Figure 25: Tube test of neonatal SMN-ASO-injected mice (FVB/N). There is no significant difference in tube 
test performance between SMA and SMA-PLS3het (n ≥ 10). 
In a last set of tests for neonatal motoric function the righting reflex test was performed on 
animals of both backgrounds (C57BL/6N and FVB/N). As in the tube test the error bars 
indicate the larger variability amongst animals within a group. Different to the tube test, on 
C57BL/6N background there were no significant differences between SMA + ASO, SMA-
PLS3het + ASO and SMA-PLS3hom + ASO detectable at any measured time point (Figure 
26). This is also true for the animals on FVB/N background that performed that test (Figure 
27). 
 
Figure 26: Righting reflex test of neonatal SMN-ASO-injected mice (C57BL/6N). There is no significant 
difference in tube test performance between SMA and SMA-PLS3het (n ≥ 10). 
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Figure 27: Righting reflex test of neonatal SMN-ASO-injected mice (FVB/N). There is no significant 
difference in tube test performance between SMA and SMA-PLS3het (n ≥ 10). 
In addition, the grip strength at P36 and P108 was measured and observed that although 
SMN-ASO-injected SMA-PLS3het and SMA-PLS3hom mice at P36 performed the test with 
diminished grip strength in comparison to the corresponding control group (HET, HET-
PLS3het and HET-PLS3hom), this parameter significantly improved in SMA-PLS3hom mice 
at P108 (Figure 28). SMA-PLS3het or SMA-PLS3hom mice that survived >250 days did not 
show any abnormal motoric movement or paralysis. Performance criteria for this test are 
mentioned in section 4.1.8. 
 
Figure 28: Grip strength test of SMN-ASO-injected mice at P36 and P108. At P108 grip strength force was 
fully restored in SMA-PLS3hom mice, reaching levels comparable to HET and HET-PLS3het mice (n ≥ 8). 
(Modified from (Hosseinibarkooie et al. 2016) by increasing the total number of analyzed animals). 
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5.7 TISSUE SPECIFIC SMN EXPRESSION AFTER SMN-ASO 
INJECTION 
Interestingly, SMN-ASO injection produced very little increase in SMN amount in the brain 
(Figure 29A), spinal cord (Figure 29B) or lung (Figure 29C), whereas the liver (Figure 29D) 
of the same animals clearly showed increased SMN expression. This result suggests that 
SMN-ASOs have a low blood-brain penetration and that the phenotypic improvements have 
to be mainly due to an inner organ rescue, which will be shown later (5.9). 
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Figure 29: Immunoblot analysis of brain, spinal cord, lung and liver lysates from uninjected and SMN-
ASO-treated SMA and HET mice. Notably is that the SMN-ASO only very slightly increased the SMN amount 
in brain, spinal cord and lung (N = 3). n. s., non-significant, ** p < 0.01, 2-tailed Student’s t test. Error bars 
represent SEM. 
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Figure 30: Immunoblot of spinal-cord lysates shows that PLS3 overexpression does not induce significant 
SMN elevation (N = 3) but a mild augmentation. n. s., non-significant by a two-tailed Student’s t test. Error bars 
represent SEM. (Taken from (Hosseinibarkooie et al. 2016)) 
 
Figure 31: ACTB and GAPDH protein expression upon PLS3 overexpression (V5 staining) does not alter. 
ACTB and GAPDH were used as housekeeping proteins and loading controls in this study. 
5.8 SMN2 RNA EXPRESSION LEVELS OF SMN-ASO TREATED MICE 
To address the question how the SMN-ASO effects the expression level of SMN2 in vivo, 
the total amount of both SMN2 transcripts, FL-SMN2 and Δ7-SMN2, was quantified. Gapdh 
was used as a internal control. To do so, the RNAs extracted from spinal cord and liver of 
the untreated SMA and HET as well as the SMN-ASO treated SMA and HET mice were 
quantified using the RiboGreen® dye (4.3.2.3). Afterwards 150 ng RNA was subjected to 
reverse transcription. The interpretation of the real-time RT-PCR revealed a substantial 
effect of the SMN-ASO regiment on the SMN2 transgene expression. The used primer for 
the real-time PCR were previously designed in our laboratory to detect only the FL- or the 
Δ7-SMN2 transcript, which was derived from the human SMN2 transgene. The quantitative 
real-time PCR was performed as described in section 4.3.3.3. The results show a highly 
significant increase of FL-SMN2 in spinal cord from P10 SMN-ASO injected mice (Figure 
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32). This is not only true for SMA mice (SMA; uninjected and SMA; 30 µg SMN-ASO) but 
also for the corresponding control groups (HET; uninjected and HET; 30 µg SMN-ASO). In 
contrary to these findings, there were no significant differences of FL-SMN2 transcript levels 
after SMN-ASO injection in liver; neither in SMA mice nor in the control group (Figure 32). 
On the other hand a tendency but not yet significant decrease of ∆7-SMN2 transcript was 
observed in this highly metabolic organ after SMN-ASO injection in both the SMA and the 
HET mice, which supports the results of the protein expression in this organ (Figure 29D). 
This effect was not observed in spinal cord. At first sight these data seem very contradictory 
to the protein expression analyses of spinal cord and liver (chapter 5.7). Due to the fact that 
all performed transcript measurements only refer to the human SMN2 transgene, small 
changes in transcript expression were detected that could have only been influenced by the 
SMN-ASO injection as this ASO is especially designed to correct the splicing defect of 
SMN2, whereas in protein expression studies in HET mice the antibody also detects SMN 
protein derived from the endogenous mouse Smn gene. Therefore, on protein level these 
small changes may be within the error range and thus not detectable. In addition, we need 
to take in consideration that there could be cell type specific regulations that influence the 
SMN-ASO stability. Posttranscriptional regulations and posttranslational modifications can 
alter the mRNA and protein stability, respectively. 
Figure 32: FL- and ∆7SMN2 levels in s. c. and liver in P10 SMA and HET (ctrl) mice with and without SMN-
ASO injection (N=3 per genotype; n=2 quantitative real-time PCR measurements per animal). n. s. non-
significant; * p < 0.05; ** p < 0.01; *** p < 0.001, 2-tailed Student’s t test. Error bars represent SD. 
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5.9 HISTOLOGY OF INTESTINE, LUNG AND HEART IN THE 
INTERMEDIATE SMA MOUSE MODEL 
PLS3 overexpression did not have a strong influence on the survival of the severely affected 
SMA mice (Ackermann et al. 2013), which we hypothesize could be due to multi-organ 
dysfunctions in this animal model (Ackermann et al. 2013; Schreml et al. 2013). We next did 
histological analyses of intestine, lung and heart, to better understand how the SMN-ASO 
injection affects the inner organ development of these mice. Subsequently, intestine, lung 
and heart tissues of SMN-ASO-injected P10 mice were collected and a Haematoxylin/Eosin 
staining of paraffin-embedded slices of these organs was performed. In addition, the weight 
of hearts of uninjected mice and ones treated with SMN-ASO were compared to each other. 
SMA-PLS3het and SMA-PLS3hom mice showed a tendency toward increased heart size in 
comparison to SMA mice (normalized to body weight) (Figure 33 and Figure 34). SMN-ASO 
injection ameliorated the multi-organ dysfunction of the lung, heart, and intestine in all SMA 
mice compared to ctrl-ASO injected mice (Figure 34). Especially the stably structured 
intestinal epithelium with more intact villi and the reorganizing secretory cells within it as well 
as the diminished emphysema with ruptured alveolar septa and enlarged alveolar spaces in 
the lung are noteworthy. Furthermore, these data show that a combinatorial therapy 
involving SMN-ASO and PLS3 overexpression has a highly beneficial ability to counteract 
SMA, as already demonstrated by natural protection in human asymptomatic SMN1-deleted 
siblings. 
 
Figure 33: An accumulative effect on the heart size was observed in SMN-ASO-injected SMA mice. The 
size further increased when PLS3 was overexpressed (N ≥ 3 per genotype). * p < 0.05; two-tailed Student’s 
t test. Error bars represent SEM. (Taken from (Hosseinibarkooie et al. 2016).) 
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Figure 34: Representative pictures of histological sections from intestine, lung, and heart (P10): 
Injection of SMN-ASO and PLS3 overexpression improved intestine, lung, and heart phenotypes in SMA mice. 
An increased number of intact intestinal villi as well as a better organization of the secretory cells, less 
emphysema with ruptured alveolar septa, enlarged alveolar spaces in the lung, and an increased heart size 
can be observed. The scale bar represents 100 µm. (Taken from (Hosseinibarkooie et al. 2016).) 
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5.10 PLS3 OVEREXPRESSION INCREASED NMJ SIZE 
To clarify whether the SMN-ASO injection combined with PLS3hom overexpression has a 
direct influence on the postsynaptic site, TVA muscle tissue was collected from all genotypes 
that are represented in Figure 35 and NMJ size was measured after bungarotoxin staining. 
Analysis of the NMJ structures revealed that injection of SMN-ASO significantly increased 
the NMJ size in both SMA and HET mice (Figure 35). An accumulative effect of SMN-ASO 
and PLS3 overexpression on NMJ size was observed at P10, and this effect was consistent 
with our previous findings regarding the role of PLS3 in NMJ structure and function 
(Ackermann et al. 2013). 
 
Figure 35: Representative pictures of NMJ (P10) stained with SV2 and NF (green) for the neuronal part and 
bungarotoxin (red) for the postsynaptic part and quantification shows that injection of SMN-ASO significantly 
increased the NMJ size in comparison to that of NMJs of untreated SMA mice at P10. Upon PLS3 
overexpression, an accumulated effect of SMN-ASO and PLS3 overexpression was observed at the NMJ level 
(n = 5 per genotype, 100 NMJs measured per animal). The scale bar represents 20 µm. (Taken from 
(Hosseinibarkooie et al. 2016). 
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5.11 PLS3 OVEREXPRESSION INCREASED THE NUMBER OF 
PROPRIOCEPTIVE INPUTS 
SMA mice emerge with poorly developed connectivity between primary proprioceptive 
afferents and MN cell bodies (Mentis et al. 2011). To investigate the influence of PLS3 in 
this context, the lumbar L4–L5 spinal region of SMN-ASO-injected mice was immunostained 
with vesicular glutamate transporter 1 (VGlut1), a well-described marker for proprioceptive 
primary afferents, and choline acetyltransferase (ChAT), a MN marker. Furthermore, 
quantification of the VGLUT1 puncta on the MN soma revealed an increased number of 
proprioceptive inputs and MN soma volume upon SMN-ASO injection. Overexpression of 
PLS3 together with SMN-ASO has an additive effect and is able to restore the reduced 
number of proprioceptive inputs on MN soma (Figure 36). 
 
Figure 36: Representative pictures of MN soma (ChAT, red) and proprioceptive input (VGLUT1, green) 
derived from SMN-ASO-injected mice (P21). Quantification shows that SMN-ASO injection and PLS3 
overexpression significantly improved the number of proprioceptive inputs on the MN soma (n ≥ 70). n. s., non-
significant; * p < 0.05; ** p < 0.01; *** p < 0.001, two-tailed Student’s t test. Error bars represent SEM. The 
scale bar represents 10 µm. (Taken from (Hosseinibarkooie et al. 2016).) 
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5.12 AXON LENGTH IS RESCUED BY PLS3 OVEREXPRESSION 
Previous work in SMN-deficient MN cultures from SMA mice or MN–like cells showed severe 
reduction in axonal length. Moreover, the main phenotype in smn-deficient zebrafish, is an 
aberrant growth of motor axons (Oprea et al. 2008). Therefore, we investigate the influence 
of PLS3 on the axon length of cultured primary murine MNs. The MN cultures were 
generated as described in section 4.2.2 and immunostained with α-ChAT and α-NF (3.8.1) 
to measure axon outgrowth of MNs (4.2.6). Figure 37 show representative pictures of MNs 
derived from SMA, SMA-PLS3het, SMA-PLS3hom, HET, HET-PLS3het, and HET-
PLS3hom mouse embryos. The quantification shown in Figure 38 demonstrates the 
rescuing effect of PLS3 on the axon length of MNs in the Taiwanese SMA mouse model. 
Figure 37: Representative pictures of MNs: nucleus (Hoechst, blue), MNs (ChAT, red) and axons (NF, 
green) derived from SMA, SMA-PLS3het, SMA-PLS3hom, HET, HET-PLS3het, and HET-PLS3hom mouse 
embryos (E13.5). The scale bar represents 50 µm. 
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Figure 38: PLS3 overexpression rescues axon length in MNs: Quantification of axon length in MNs: N = 3 
per genotype, 100 cells measured per cell line. The axon length in SMA-PLS3het and SMA-PLS3hom versus 
SMA MNs was significantly different. * p < 0.05; *** p < 0.001, 2-tailed Student’s t test. Error bars represent 
SD. 
5.13 SMA IMPAIRS ENDOCYTOSIS, WHICH IS RESCUED BY PLS3 
OVEREXPRESSION 
PLS3 is an F-actin-binding and -bundling protein that is involved in many cellular processes 
(Delanote et al. 2005; Pollard and Borisy 2003). Knockdown of Sac6p, the ortholog of PLS3 
in yeast, leads to disturbed endocytosis (Kubler and Riezman 1993). Moreover, F-actin, 
which is important for all types of endocytosis (Engqvist-Goldstein and Drubin 2003; Doherty 
and McMahon 2009), has been shown to be disturbed in SMA (Ackermann et al. 2013; 
Francesca et al. 2016; Bowerman et al. 2007). Therefore, in our laboratory we hypothesized 
that reduced SMN amount might impair endocytosis and can be rescued by PLS3 
overexpression. 
5.13.1 FITC-Dextran uptake in murine embryonic fibroblasts 
To verify this theory, first the uptake of fluorescently labeled dextran (FITC-Dex) by fluid-
phase endocytosis (Doherty and McMahon 2009) was measured in murine embryonic 
fibroblast cell lines (MEFs) derived from SMA, SMA-PLS3het, HET, and HET-PLS3het mice. 
Fluorescence microscopy imaging was used to quantify FITC-Dex uptake in cells fixed at 
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different time points. A strong reduction in endocytic uptake of FITC-Dex was observed in 
SMA compared to HET MEFs (Figure 39), but uptake was significantly restored by PLS3 
overexpression (Figure 40). 
Figure 39: Representative pictures of MEFs: nucleus (Hoechst, blue), actin filaments (Phalloidin, red) and 
FITC-Dextran uptake (green) derived from SMA, SMA-PLS3het, HET, and HET-PLS3het mouse embryos 
(E13.5). The scale bar represents 50 µm. 
 
Figure 40: PLS3 Overexpression Rescues Impaired Endocytosis in MEFs: Quantification of FITC-Dex 
uptake in MEFs was performed via fluorescence-intensity analysis (N = 3 per genotype and time point, 100 
cells measured per cell line). The amount of uptake in SMA versus SMA-PLS3het mice was significantly 
different at 10 and 30 min. (Taken from (Hosseinibarkooie et al. 2016).) 
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5.13.2 FM1-43 Endocytosis Experiment 
Additionally, we performed an electrophysiological experiment, using ex vivo preparations 
of TVA muscle dissected from P10 mice. Muscles were kept in physiological solutions to 
maintain alive. All electrophysiological experiment were performed by Dr. Laura Torres-
Benito, who is an expert on the field. Electrical stimulation of the N. intercostalis innervating 
the TVA muscle (see sketch Figure 41A) was performed in two independent sets: a low-
frequency set at 5 Hz and a high-frequency set at 20 Hz for analysis of FM1-43 uptake. As 
previously shown in a study performed in hippocampal neurons, low-frequency stimulation 
mainly triggers clathrin-mediated endocytosis (CME), whereas high-frequency stimulation 
activates clathrin-independent endocytosis (CIE) or activity-dependent bulk endocytosis 
(ADBE) (Kononenko et al. 2014). Postsynaptic sites were stained with bungarotoxin 
conjugated with Alexa647 (BTX-Alexa647). Through delimitation of these areas, the mean 
intensity of the FM1-43 at the presynaptic terminals could be quantified Figure 41B. At low-
frequency stimulation, FM1-43 intensity was significantly reduced in SMA compared to HET 
mice (Figure 41B and Figure 41C), whereas in SMA-PLS3het and SMA-PLS3hom NMJs, 
endocytosis was restored to HET levels upon 5 Hz stimulation (Figure 41C). 
 
Figure 41: PLS3 overexpression rescues impaired endocytosis at presynaptic sites of NMJs in SMA 
mice. (A) Experimental setup for stimulation of the N. intercostalis innervating the TVA muscle. (B) 
Representative pictures of NMJs from HET, SMA, and SMA-PLS3hom muscles. Staining of postsynaptic 
receptors (BTX-Alexa647, gray) helped to define the area in which FM1-43 uptake (red) at the presynaptic 
terminals was analyzed (n = 3 per genotype, ~100 NMJs measured per genotype). The scale bar represents 
10 mm. (C) Quantification of the FM1-43 mean intensity at the presynaptic terminals at P10 in TVA muscles 
without ASO injection under low frequency stimulation (5 Hz, 1 s). n.s., non-significant; ***p < 0.001, two-tailed 
Student’s t test. Error bars represent SEM. (Modified from (Hosseinibarkooie et al. 2016).) 
Presynaptic uptake of FM1-43 dye without electrical stimulation was excluded Figure 42A. 
NMJs of TVA from SMA mice are reported to be smaller (Torres-Benito et al. 2011; Murray 
et al. 2008). FM1-43-intensity was correlated to NMJ size to confirm that these two 
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parameters do not correlate Figure 42C. At a high-frequency stimulation of 20 Hz, 
endocytosis was also decreased in SMA compared to HET mice. PLS3 overexpression in 
both, SMA-PLS3het and SMA-PLS3hom NMJ, rescued the impaired phenotype Figure 42B. 
These experiments underline how PLS3 counteracts the disturbances within the 
endocytosis pathway that occur in SMA pathology at the NMJ. 
 
Figure 42: FM1-43 uptake at the presynaptic site in TVA muscle is stimulation-dependent. A) WT TVA 
muscles at P21 treated with FM1-43 dye with and without stimulation. Muscles without stimulation do not show 
any FM1-43 staining, proving that uptake of FM1-43 dye is stimulation-dependent. Postsynaptic receptors 
staining (BTX-647, grey) was used to define the area to analyze the FM1-43 uptake (red) at the presynaptic 
terminals. Scale bar: 10 µm. B) Quantification of the FM1-43 mean intensity at the presynaptic terminals in 
P10 TVA muscles without ASO injection under high frequency stimulation (20 Hz, 1s). C) NMJ size does not 
influence the uptake of FM1-43. Plotting the amount of FM1-43 uptake against the NMJ size did not show any 
correlation between the uptake amount and the endplate size in both HET and SMA TVA muscles (n = 3 per 
genotype, ~100 NMJs measured per genotype). n.s. non-significant; ** p < 0.01; *** p < 0.001, 2-tailed 
Student’s t test. Error bars represent SEM. (Modi from (Hosseinibarkooie et al. 2016).) 
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6. Discussion 
6.1 PLS3 MEDIATES A PHENOTYPIC RESCUE IN AN INTERMEDIATE 
SMA MOUSE MODEL 
The actin filament binding and bundling protein PLS3 was reported as the first SMA modifier 
besides SMN2 that was highly upregulated in SMN1-deleted individuals of six discordant 
families of SMA (Oprea et al. 2008). Indeed, when iPSCs were derived from fibroblasts from 
SMA patients and asymptomatic SMN1-deleted siblings and subsequently differentiated into 
MNs, PLS3 upregulation was observed only in these unaffected individuals, importantly in 
the disease-relevant cell type (especially in the growth cones) (Heesen et al. 2016). 
However, previous studies performed in two severely affected mouse models: Taiwanese 
and Δ7 SMA did not reveal the whole spectrum of the PLS3 protective effects (McGovern et 
al. 2015; Ackermann et al. 2013). PLS3 did not increase survival, despite ameliorating NMJ 
formation and maintenance as well as motoric abilities in Taiwanese SMA neonatal mice 
(Ackermann et al. 2013). These results, as well as the fact that every asymptomatic SMN1-
deleted individual has at least 3 – 4 SMN2 copies, led to the assumption that it is necessary 
to increase SMN levels above a certain threshold for PLS3 to fully unfold its modifying ability 
(Hosseinibarkooie et al. 2016). Comparing previous findings that are described above with 
the present study, we can conclude that our threshold hypothesis was correct as we 
observed only in the intermediate SMA mice that PLS3 provides an extensive phenotypic 
rescue, involving survival (5.4), weight progression (5.5), motoric ability (5.6), inner organ 
defects (5.9), NMJ integrity (5.10) and proprioception (5.11) as well as improved endocytic 
uptake (5.13). Therefore, using SMN-ASO injection to induce an intermediate phenotype in 
the severely affected Taiwanese SMA mice did not only provided us with a model that 
resembles more the condition of asymptomatic SMN1-deleted individuals but also supported 
the idea that combinatorial therapy of suboptimal doses of SMN-ASO in addition to 
compounds that either directly elevate PLS3 levels or compensate for the defects in the 
endocytosis pathway might be a feasible strategy for future clinical trials. 
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6.2 WHY ARE INTERMEDIATELY-AFFECTED SMA MOUSE MODELS 
NECESSARY BUT CHALLENGING TO PRODUCE? 
In severe SMA mouse models with extremely low SMN levels, defects in a plethora of 
pathways apart from the neuromuscular system have been reported, especially affecting 
non-neuronal cell types and organs and leading to severe multi-organ failure (Hamilton 
and Gillingwater 2013; Sleigh et al. 2011). However, the protective modifying genes have 
been identified in asymptomatic individuals who would hypothetically present a milder 
form of SMA. Therefore, it is more suitable to use SMA models of an intermediate 
phenotype when searching for defects of cellular mechanisms in SMA pathology that are 
restored by protective modifying genes. As two human SMN2 copies on a murine Smn-
null background produce a severe phenotype and result in early death, while mice with 
three SMN2 copies are already asymptomatic, it is rather challenging to produce a 
genetically engineered intermediate or mild SMA mouse model (Monani et al. 2000b; 
Hsieh-Li et al. 2000; Riessland et al. 2010). Indeed, a systemic approach aiming at 
generating intermediate SMA type 2 or 3-like mouse by the use of complete allelic series 
resulted in only these two phenotypic extremes: either severe or asymptomatic (Osborne 
et al. 2012). 
Nonetheless, several groups successfully generated mice with intermediate phenotype 
as described in section 1.1.6.4 and 1.1.6.5. The Smn2B/KO mouse model has the 
advantage to analyze influences of protective modifying genes in an SMN2-independent 
context (Bowerman et al. 2012a), whereas the Burgheron mouse offers the great 
possibility to use a combined treatment strategy of protective modifiers in addition to 
SMN-ASO or morpholino injection, as well as to explore the window for therapeutic 
intervention (Bogdanik et al. 2015). 
Intermediate SMA mouse models offer an opportunity to answer whether therapeutic 
approaches are temporarily limited to presymptomatic stages or if they extend even to 
later time points after the onset of the symptoms (Bogdanik et al. 2015). Treatment with 
compounds such as SMN-ASOs or morpholinos either solely injected into the severe 
SMA mouse models or as combined therapy similar to the present study, provide 
powerful tools to translate new findings to the human SMA pathology more efficiently 
and unravel pathway defects within target tissues. Hence, patients benefit from new 
therapies with more specific target strategies. 
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6.3 COMBINED EFFECT OF SMN-ASO AND PLS3 OVEREXPRESSION 
ON THE NEURONAL CIRCUITRY OF SMA ANIMALS 
Pre-symptomatic treatment with higher doses of SMN-ASO fully rescues the SMA 
phenotype in mice, with the exception that these animals manifest a smaller body size (Hua 
et al. 2010; Porensky et al. 2012). Therefore, in this study we applied low doses of SMN-
ASO, as we did not aim for a complete rescue, but rather an intermediate SMA model, which 
would serve as a platform to investigate the effect of elevated PLS3. As described in sections 
4.1.6 and 5.3, we subcutaneously injected the Taiwanese mice at P2 and P3 with suboptimal 
doses of SMN-ASO (30 µg per injection) to increase SMN amounts in order to compensate 
for the described inner organ failure (5.9) and thereby increasing survival from 14 to 28 days. 
However, despite injecting SMN-ASO during early development and maturation of NMJs, 
the SMN increase was not sufficient to compensate for all defects within the neuronal 
circuitry. It increased NMJ size in comparison to NMJs of untreated mice (5.10) but the 
number of proprioceptive inputs and the MN soma size is still smaller in comparison to 
controls (5.11). Similarly, in mildly affected SMA patients, the SMN amount seems to be 
sufficient to maintain its housekeeping function in all cells except MNs (Wirth et al. 2015; 
Hamilton and Gillingwater 2013). In comparison to previously reported impairment of 
sensory motor connectivity (Mentis et al. 2011), we observed that elevated SMN amounts 
in combination with PLS3 overexpression, had a great beneficial impact on the disturbed 
neuronal circuitry of SMA mice. Among these there are increased NMJ size, which reflects 
an improved AChR clustering, and elevated proprioceptive inputs at the MN soma, as well 
as increased MN soma size (see also section 5.10 and 5.11). Interestingly, even in MNs 
derived from severely affected Taiwanese mice, PLS3 overexpression alone led to 
increased length of the main axon (see also section 5.12). As mentioned above, SMN-ASO 
or morpholino injection needs to be done during early developmental stages (neonatal mice) 
as higher amounts of SMN protein are required before P17 during development and 
maturation of NMJs (Kariya et al. 2014). If the SMN elevation in either low-dose pre-treated 
Δ7 SMA mice or in an intermediate mouse model is achieved later, it leads to only very 
moderate rescuing effects (Feng et al. 2016; Bogdanik et al. 2015; Zhou et al. 2015). 
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6.4 PLS3 OVEREXPRESSION RESCUES SURVIVAL IN THE 
INTERMEDIATE, BUT NOT IN THE SEVERE SMA MICE 
As previously reported, PLS3 compensated for some symptoms of SMN deficiency in SMA-
PLS3het mice, considering its restoring effect at the NMJ. Among these there is an improved 
connectivity at the presynaptic site, delayed axonal pruning, increased F-actin levels and 
AChR clustering at the postsynaptic site (Ackermann et al. 2013). Despite these 
improvements, elevated PLS3 was still not able to increase survival rate or weight 
progression, even if expressed homozygously (see also section 5.1). Our findings were 
reproduced by another group using a different severe SMA mouse model (McGovern et al. 
2015). In these Δ7 SMA mice, overexpression of PLS3 did not improve the SMA phenotype. 
They detected elevated mRNA PLS3 levels in the MNs and increased PLS3 protein 
overexpression throughout the whole spinal cord. This augmentation of PLS3 did neither 
change survival or weight nor improved the measured quantal content at the NMJ. Hence, 
as stated above, PLS3 cannot compensate for the inner organ dysfunctions in the severely 
affected Taiwanese or Δ7 SMA mice. As a consequence, these animals die early due to 
multi-organ failure. 
Our SMN-ASO-induced intermediate mouse model survived for approximately one month 
and PLS3 overexpression prolonged the survival to more than 400 days in 30% and 250 
days in 60% of all mice tested. In 25% of all SMN-ASO injected animals, mice died as early 
as untreated ones, despite PLS3 overexpression. We assumed that the SMN-ASO was not 
equally distributed and these suboptimal doses were not uniformly dispersed among all 
affected tissues, which caused the early death. However, in the majority of animals, PLS3 
overexpression led to a marked increase in survival, suggesting that PLS3 overexpression 
is able to counteract the cellular defects caused by SMN deficits (Hosseinibarkooie et al. 
2016). 
Interestingly, when using the self-complementary adeno-associated virus 9 (scAAV9) for 
gene delivery into MNs of SMA mice by intravenous (Foust et al. 2010; Valori et al. 2010; 
Dominguez et al. 2011) or intramuscular injection (Benkhelifa-Ziyyat et al. 2013), the SMN 
gene was delivered to the spinal cord and thereby decreased disease severity in SMA mice. 
scAAV9-SMN is able to cross the blood brain barrier (BBB) and efficiently transduce MNs in 
the lumbar region of the spinal cord as well as muscle tissue. In the context of finding stably 
functioning intermediate or mild SMA animal models to test further modifiers, this technique 
could be very promising. 
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As mentioned earlier, SMN upregulation after disease onset did not effectively ameliorate 
the outcome of the SMA phenotype in mice (Bogdanik et al. 2015; Zhou et al. 2015; Feng 
et al. 2016). In case of type II and III SMA patients, an SMN-independent therapy targeting 
impaired endocytic processes and/or increasing the F-actin amounts could be more 
effective. As the majority (60%) of all SMA patients are SMA type I (Monani and De Vivo 
2014) and SMN-ASO therapy is limited by the SMN2 copy number, SMN elevation may be 
insufficient to protect MNs, cure SMA life-long, or rescue all additional symptoms, such as 
cardiac problems, spinal deformities and joint contractures. Therefore, SMA type I patients 
will benefit the most from combinatorial therapy of SMN-ASO and an SMN2-independent 
modifier and may have a great potential for future therapy strategies as we proved in vivo. 
6.5 PLS3 AND ITS IMPACT IN NON-NEURONAL TISSUES 
In several previous studies, muscle defects and dysfunction of non-neuronal tissues in SMA 
patients, as well as inner organ defects in mouse models of SMA have been reported and 
characterized in more detail (Schreml et al. 2013; Riessland et al. 2010; Shababi et al. 2010; 
Hayhurst et al. 2012; Shababi et al. 2012; Bevan et al. 2010; Heier et al. 2010; Butchbach 
et al. 2010; Bowerman et al. 2012b; Cifuentes-Diaz et al. 2001; Hua et al. 2011; Vitte et al. 
2004; Le et al. 2011; Talbot 1999; De Sanctis et al. 2016; Shababi et al. 2014). In this 
context, muscular defects that did not secondarily occur due to decreased innervations but 
primarily due to SMN deficits are outlined in the following. Interestingly, in severely affected 
SMA mice abnormal differentiation and myotube formation (Hayhurst et al. 2012) have been 
described. Many different features that contribute to an early death of the Taiwanese SMA 
mice were previously reported and well characterized. Among these are not only changes 
in the molecular composition of skeletal muscle (Mutsaers et al. 2011) but also alterations 
of lung tissue described with dark red spots and ruptured alveolar septa and emphysema 
(Schreml et al. 2013). Additionally, these SMA mice suffer from diarrhea and the reduced 
numbers of villi in the small intestine. They show a prolapsed rectum, as well as intramural 
edema in the lamina propria (Schreml et al. 2013). Most importantly, a cardiac phenotype is 
well characterized in all commonly used severely affected SMA mouse models (Monani et 
al. 2000a; Riessland et al. 2010; Bowerman et al. 2012a). Noteworthy are Intraventricular 
septum remodelling and thin ventricular walls (Hua et al. 2011; Shababi et al. 2010), as well 
as vascular remodelling with interstitial fibrosis (Shababi et al. 2010), decreased numbers 
of capillaries and smaller cardio-myocytes (Shababi et al. 2012). Moreover, previous studies 
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revealed that transgenic mice lacking murine Smn in the liver are embryonic lethal (Vitte et 
al. 2004). They have reduced levels of Insulin-like growth factor binding protein acid labile 
subunit (IGFALS) in the liver (Hua et al. 2011), concomitant with glucose intolerance, 
hypersensitivity to insulin, hypoglycemia and hyper-glucagonemia, which have been 
reported in Smn2B/KO mice (Bowerman et al. 2012b) and Δ7 SMA mice (Butchbach et al. 
2010). In the past, these characterizations of inner organ defects primarily contributed to a 
better understanding of – primary or secondary – non-neuromuscular organ involvement in 
SMA pathology and led to improved standards of care and reassessment of how to 
investigate SMA patients clinically. Interestingly, overexpression of PLS3 in the severely 
affected Taiwanese SMA mice increased muscle fibre size (Ackermann et al. 2013) but 
neither diminished intestinal problems (such as diarrhoea) nor increased heart size (see 
also section 5.9 and (Hosseinibarkooie et al. 2016)). PLS3 overexpression only reduced 
these inner organ impairments in the SMN-ASO-induced intermediate SMA mouse model, 
in which sufficient SMN amounts are present. In this case, SMA-PLS3het and SMA-
PLS3hom mice showed a tendency towards increased heart size in comparison to SMA 
mice. Moreover, SMN-ASO injection ameliorated the inner organ impairments of the lung, 
heart, and intestine in SMA mice and were further improved in combination with PLS3 
overexpression. The stably structured intestinal epithelium with more intact villi and the 
reorganizing secretory cells within it, as well as the diminished emphysema with ruptured 
alveolar septa and enlarged alveolar spaces in the lung are noteworthy (5.9). Taken 
together, these data additionally underline that a combinatorial therapy involving SMN-ASO 
and PLS3 overexpression has a highly beneficial ability to counteract SMA, as already found 
by natural protection in asymptomatic SMN1-deleted individuals. 
6.6 ENDOCYTOSIS AND SYNAPTIC VESICLE RECYCLING ARE IMPAIRED 
IN SMA AND RESCUED BY PLS3 
PLS3, which has been shown to be a F-actin-binding and -bundling protein, impairs 
endocytosis when knocked out in yeast (Kubler and Riezman 1993). As mentioned above 
(1.4), numerous studies have already addressed the role of actin as a key player in 
endocytosis. Importantly, actin assists at the remodelling of the cell surface to allow inward 
movement of vesicles (Smythe and Ayscough 2006). In the context of SMA, we have 
previously reported that SMN-depleted cells show reduced F-actin amounts and therefore, 
we hypothesized that this effect could be due to a disturbed transport of ß-actin mRNA along 
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the axons (Ackermann et al. 2013; Gabanella et al. 2016; Oprea et al. 2008). In several 
animal models of SMA it could be demonstrated that many F-actin-dependent processes 
are impaired, including axonal growth, proper NMJ connectivity, neurotransmission, 
synaptic-vesicle recycling and proprioceptive inputs at MN soma (Ackermann et al. 2013; 
Mentis et al. 2011; Oprea et al. 2008; McWhorter et al. 2003; Dimitriadi et al. 2010). All of 
these defects could be either ameliorated or completely restored by PLS3 overexpression 
(Oprea et al. 2008; Ackermann et al. 2013; Hao le et al. 2012). In section 5.13, we have 
demonstrated that reduced SMN levels lead to reduced endocytosis in murine embryonic 
fibroblasts, which could be restored by PLS3 overexpression. Moreover, we have recently 
reported that this finding also applies to NSC34 cells and at the NMJs, as shown by FM1-
43 endocytic uptake under low- (Figure 41) and high-frequency (Figure 42) conditions. As 
PLS3 rescued disturbed endocytosis under both conditions, we confirmed that it is involved 
in clathrin-mediated endocytosis (CME), as well as clathrin-independent endocytosis (CIE) 
or activity-dependent bulk endocytosis (ADBE). PLS3 restored endocytosis and the SMA-
related phenotype in mouse and/or zebrafish and similar to the findings in yeast, siRNA-
mediated knockdown of PLS3 reduced endocytic uptake in various cell types 
(Hosseinibarkooie et al. 2016). In SMA mice, reduced F-actin amounts lead to reduced 
numbers of vesicles in the readily releasable pool of synaptic vesicles, which are needed for 
proper neurotransmission. Their size is smaller and the depletion and refilling time constants 
tend to be slower (Torres-Benito et al. 2012). F-actin is a crucial player in all types of 
endocytosis (Mooren et al. 2012; Doherty and McMahon 2009), and its inhibition reduces 
the endocytosis in neurons under high-rate stimulation (Watanabe et al. 2013). Our recently 
published data underline these findings and support the idea that PLS3 overexpression is 
able to rescue the impaired endocytosis in SMA through the crucial role of F-actin in 
endocytosis (Hosseinibarkooie et al. 2016). As the calcium-binding ability of PLS3 via its 
EF-hands (Lyon et al. 2014) seems to be essential for PLS3 to compensate for SMN loss, 
we hypothesized that decreased endocytosis might be a result of combined reduced calcium 
influx and F-actin dynamics (See et al. 2014). The fact that SMA MNs show disturbed 
calcium homeostasis (Ruiz et al. 2010) further strengthens this concept. 
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6.7 THE POWER OF GENETIC MODIFIERS 
This work is an outstanding example of how the power of genetic modifiers can be used as 
a precise tool to identify key cellular mechanisms, molecular pathways and protein networks 
that successfully inhibit or counteract the disease-causing genes and/or processes. Figure 
43 shows a model of the compensatory role of PLS3 and Coronin1C (CORO1C: an 
interacting partner of PLS3 and an additional disease modifier of SMA) in the process of 
endocytosis in SMA (Hosseinibarkooie et al. 2016). Our gained knowledge about these 
modifiers might pave the way for the development of new therapeutic strategies targeting 
the affected endocytic mechanism in SMA in addition to pharmacological compounds that 
induce SMN expression or stability. 
 
Figure 43: A model presenting the compensatory role of PLS3 and CORO1C in the process of endocytosis 
in SMA. CME and ADBE stand for clathrin-mediated endocytosis and activity-dependent bulk endocytosis, 
respectively. (Taken from (Hosseinibarkooie et al. 2016).) 
In a more general context of genetic modifiers, it is important to investigate their mode of 
action as well as their role within the pathway or protein network in the context of the 
disease-causing gene. This means that the modifying genes can act upstream or 
downstream of the disease-causing gene, by either influencing their expression and/or 
function or compensating for imbalances and defects in a pathway affected by them, 
respectively. Their compensation can be directly within the affected protein complex or 
totally independent. Numerous pathogenic mutations have been unexpectedly identified in 
healthy individuals, opening a fully now era and allowing us to better understand diverse 
counteracting protein networks and their regulation, which ultimately will result in 
development of novel therapeutic strategies (Hosseinibarkooie et al. 2016). 
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6.8 OUTLOOK 
Identification of PLS3 as a first SMN-independent protective modifier is a starting point to 
develop new treatment strategies for neurodegenerative disorders including SMA, 
Parkinson or ALS. PLS3 did not only help to identify endocytosis as a main cellular pathway 
disturbed in SMA pathology but also provided a more detailed insight into the molecular 
mechanisms and the protein networks, in which PLS3 and the disease-causing SMN1 gene 
are involved. 
In the meanwhile, additional asymptomatic SMN1-deleted individuals had been identified. 
Most interestingly, in these cases PLS3 upregulation has been excluded. 
(1) There is a good reason to assume that other SMA modifiers do exist within the human 
population (Bernal et al. 2011) and unpublished data from our lab confirmed that at least 
one additional modifier is also improving the SMA phenotype via the endocytosis 
pathway (Riessland et al, AJHG, under review 2016). 
(2) In an additional screening for SMA modifiers, several other modifiers with direct roles in 
endocytosis have been identified in worm (Dimitriadi et al. 2010). Further studies are 
required to properly understand the major impaired type of endocytosis as well as other 
modifying factors (in addition to reduced F-actin amounts in the presynapse) that 
determine the endocytic traffic in SMA. 
(3) As described in section 1.1.6, several other research groups successfully generated 
different intermediate mouse models that are not drug-induced but genetically 
engineered. These could also be relevant for future studies of modifiers and drug design 
(Bogdanik et al. 2015). 
(4) In this context, the advantages and weaknesses of pharmacologically induced 
intermediate SMA animal models versus genetically engineered ones (also see section 
1.1.6) need to be discussed and evaluated in future studies. 
(5) As a side effect, while studying SMA pathology in intermediate SMA mouse models, an 
extraordinary progress has been achieved in the development of using antisense 
oligonucleotides (ASOs) such as morpholinos or RNAs (Lim and Hertel 2001; Cartegni 
and Krainer 2003; Dickson et al. 2008; Hua et al. 2010; Hua et al. 2011) in order to 
correct the SMN2 splicing pattern towards increased levels of FL-SMN transcripts (see 
also section 1.1.7). In future studies, the idea of individual drug design to target specific 
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dysfunctions such as the SMN2 splicing defect (Rigo et al. 2012) should also be 
translated to extenuate pathomechanisms in other neurodegenerative pathologies 
equally successfully. They are currently used in ongoing clinical trials in SMA type I to 
III patients (http://www.clinicaltrials.gov). Further outcome of these studies can give new 
input for development of target-specific drug-design. 
(6) New NGS technologies may help with the development of future studies in healthy 
individuals carrying pathogenic mutations in order to unravel new protective modifiers 
and eventually help to understand disease-relevant pathways in humans 
(Hosseinibarkooie et al. 2016). 
Firstly, we used SMN-ASO injection as a means to induce an intermediate phenotype in the 
severely affected Taiwanese SMA mice to establish an animal model with a certain SMN 
threshold that resembles more the situation in asymptomatic SMN1-deleted individuals. 
Secondly, we thereby learned from our model that combined therapy of suboptimal doses 
of SMN-ASO in addition to compounds that either directly elevate PLS3 levels or 
compensate for the defects in the pathway of endocytosis, might be a logical strategy for 
future clinical trials. 
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7. Summary 
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder 
characterized by the loss of α-motor neurons in the anterior horns of the spinal cord. This 
leads to atrophy of proximal symmetrical muscles and paralysis. Patients suffering from 
SMA in almost all cases show homozygous absence of the survival of motor neuron 1 gene 
(SMN1) and the severity of the disease is inversely correlated with the copy number of the 
main disease modifying gene survival motor neuron 2 (SMN2). 
Rarely, individuals with homozygous SMN1-deletion remain asymptomatic, suggesting the 
action of modifying gene(s). Plastin 3 (PLS3) – a F-actin binding and bundling protein - has 
been identified as a protective modifier showing high expression in SMN1-deleted 
asymptomatic siblings of SMA patients. PLS3 is highly expressed in spinal cord and axonal 
growth cones. PLS3 overexpression rescues the axonal outgrowth phenotype in SMA motor 
neuron cultures and SMA zebrafish (Oprea et al. 2008). Severely affected SMA mice 
carrying heterozygously a transgenic PLS3 overexpressing allele show improved motoric 
abilities as a consequence of improved innervation at neuromuscular junctions (NMJ), 
increased NMJs and muscle fibre size as well as an increase of proprioceptive input on 
motor neuron (MN) soma. Most importantly, PLS3 overexpression delays axon pruning and 
improves connectivity of the presynapse to motor endplates. Nonetheless, survival is only 
marginally increased by a few days, as a consequence of massive impairment of inner 
organs in SMA mice, which is not rescued by PLS3 overexpression (Ackermann et al. 2013). 
As PLS3 overexpression ameliorates some SMA hallmarks in the severe SMA mouse 
model, but its modifying function is likely diminished by the multi-organ impairment, we 
decided to study the effect of elevated PLS3 in an intermediate SMA mouse model, which 
would more faithfully model the condition of initially identified asymptomatic individuals. To 
do so, we made use of a low dose SMN-antisense oligonucleotide (ASO) that allows SMN2 
splice correction (Hua et al. 2011). 
In this study, (1) an intermediately-affected SMA mouse model was produced by 
presymptomatic subcutaneous injection of low dose SMN-ASOs into the severely-affected 
SMA mouse model; (2) SMN-ASO treated SMA mice on congenic FVB/N background 
showed a much larger variability in survival than on C57BL/6N background. (3) The optimal 
conditions turned out to be 30 µg SMN-ASO, injected twice at P2 and P3 in C57BL/6N SMA 
mice. These mice showed an elongated lifespan from 14 to 28 days. (4) The suboptimal 
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doses of SMN-ASO considerably decreased inner organ defects including intestine, lung 
and heart. (5) Additional overexpression of the PLS3 transgene either heterozygously or 
homozygously rescued survival from 28 to >250 days, weight and motoric abilities (grip 
strength force and tube test). These data proved that PLS3 is a protective modifier of SMA 
if elevated in an animal model that resembles the situation in the asymptomatic SMN1-
deleted individuals. (6) In this low dose SMN-ASO injected intermediate SMA mouse model, 
PLS3 counteracts the defects within the neuronal circuitry by increasing NMJ size and 
thereby stabilizing AChR clustering at the postsynaptic site. Presynaptically, PLS3 increases 
the number of proprioceptive inputs at the MN soma and leads to enlarged MN soma size. 
(7) Even in MNs isolated from the severely affected SMA mouse model, PLS3 
overexpression led to an increased length of the main axon. (8) As PLS3 knockout in yeast 
impairs endocytosis (Kubler and Riezman 1993), we hypothesized that disturbed 
endocytosis might be a key cellular mechanism underlying impaired neurotransmission and 
neuromuscular junction maintenance in SMA. Indeed, SMN deficit dramatically reduced 
endocytosis in murine embryonic fibroblasts, which was restored to control levels by 
overexpression of PLS3. 
Taken together, our findings in transgenic SMA mice demonstrate the efficacy of a combined 
treatment with SMN-ASO in addition to PLS3 overexpression, rather than solely increasing 
SMN levels. Hence, we suggest that compounds, which can restore endocytosis in 
combination with SMN-ASO therapy might not only improve the SMA phenotype but maybe 
even result in a complete rescue, and this possibility will be tested in future studies. 
Zusammenfassung 101 
 
8. Zusammenfassung 
Die spinale Muskelathrophie (SMA) ist eine autosomal rezessive neurodegenerative 
Erkrankung, die durch den Verlust von α-Motoneuronen in den ventralen Hörnern des 
Rückenmarks charakterisiert ist. Dies führt zum Muskelschwund der proximalen 
symmetrischen Muskeln mit einhergehenden Lähmungserscheinungen. Patienten, die an 
SMA erkrankt sind, weisen nahezu immer einen homozygoten Verlust des Survival of motor 
neuron 1 Gens (SMN1) auf und es gibt eine reziproke Korrelation zwischen dem 
Schweregrad der Erkrankung und der Kopienzahl des primären modifizierenden Gens, 
Survival of motor neuron 2 (SMN2). 
In seltenen Fällen bleiben jedoch Menschen, die einen homozygoten SMN1 Verlust 
aufweisen, asymptomatisch, was auf die Anwesenheit weiterer modifizierender Gene 
schließen lässt. Plastin 3 (PLS3) – ein F-Aktin-bündelndes und -bindendes Protein – wurde 
als solch ein protektives krankheitsmodifizierendes Gen identifiziert, indem es in den SMN1-
negativen asymptomatischen Geschwistern von SMA Patienten besonders stark exprimiert 
wurde. Es stellte sich heraus, dass PLS3 sehr stark im Rückenmark und in den axonalen 
Wachstumsknospen exprimiert wird. Die Überexpression von PLS3 stabilisiert das axonale 
Längenwachstum in SMA Motoneuronkulturen und im SMA Zebrafischmodell (Oprea et al. 
2008). Schwer erkrankte SMA Mäuse, die heterozygot ein PLS3 überexprimierendes 
Transgen tragen, zeigen verbesserte motorische Fähigkeiten in Folge von verbesserter 
Innervierung und vergrößerter Fläche der neuromuskulären Endplatten und größeren 
Muskelfasern, ebenso wie von erhöhten afferenten Synapsen auf den Zellkörpern der 
Motoneurone. Hervorzuheben ist, dass die Überexpression von PLS3 die axonale 
Rückbildung verzögert und somit die Verbindung der Präsynapse zur motorischen Endplatte 
unterstützt. Nichtsdestotrotz, die PLS3-Überexpression erhöhte die Überlebensrate der 
SMA Mäuse nur gering um wenige Tage, aufgrund von extremen Defekten der inneren 
Organe in SMA Mäusen, welche nicht verbessert werden konnten (Ackermann et al. 2013). 
Da PLS3-Überexpression einige SMA Merkmale im schwer betroffenen Mausmodell 
verbesserte, jedoch in seiner Funktion als modifizierendes Gen durch das Versagen 
mehrerer Organe abgeschwächt wurde, entschieden wir, den Effekt des PLS3-Anstiegs in 
einem intermediären SMA Mausmodell zu studieren, das besser den Phänotyp der 
asymptomatischen Menschen wiederspiegelt. Hierzu verwendeten wir geringe Mengen 
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eines SMN-Antisense-Oligonukleotids (ASO), das einen Defekt im SMN2 Splicing korrigiert 
(Hua et al. 2011). 
In der vorliegenden Arbeit wurden folgende Erkenntnisse hervorgebracht: (1) Durch 
präsymptomatische subkutane Injektion geringer Mengen SMN-ASOs in das schwer 
betroffene SMA Mausmodell haben wir ein mittelschwer betroffenes SMA Mausmodell 
entwickelt; (2) Die SMN-ASO behandelte Mäuse zeigten auf einem kongenen FVB/N 
Hintergrund stärkere Schwankungen in der Überlebensrate als auf einem C57BL/6N 
Hintergrund; (3) Wir haben als die optimale Applikation des SMN-ASOs in C57BL/6N SMA 
Mäuse eine Injektion von 30 µg an den Tagen P2 und P3 erarbeitet. Die Überlebensrate in 
den SMN-ASO injizierten Mäusen wurden von 14 auf 28 Tage verlängert; (4) Bereits diese 
suboptimale Dosis von SMN-ASO verringerte beträchtlich die Defekte der inneren Organe, 
einschließlich Darm, Lunge und Herz; (5) Zusätzliche hetero- oder homozygote 
Überexpression des PLS3 Transgens erhöhte die Überlebensrate von 28 auf >250 Tage, 
verbesserte die Gewichtszunahme und die motorischen Fähigkeiten. Dies bestätigt die 
Funktion von PLS3 als ein protektives modifizierendes Gen gegen SMA, sobald es in einem 
Tiermodell überexprimiert wird, das besser der Ausgangssituation der asymptomatischen 
SMN1-negativen Menschen entspricht; (6) In diesem SMN-ASO-induzierten intermediären 
SMA Mausmodell steuert die PLS3 Überexpression den Defekten innerhalb des neuronalen 
Schaltungskreises durch eine Vergrößerung der motorischen Endplatte und einer damit 
einhergehenden Stabilisierung der postsynaptischen AChR Clusters, entgegen. 
Präsynaptisch erhöht PLS3 die Anzahl der afferenten Synapsen an die Zellkörper der 
Motoneurone und führt zu einer Vergrößerung der motoneuronalen Zellkörper; (7) 
Interessanterweise führt die PLS3 Überexprimierung selbst in Motoneuronen, die aus 
schwer betroffenen SMA Mausembryonen isoliert wurden, zu einem verlängerten 
Hauptaxon; (8) Da PLS3 Knockout die Endozytose in Hefen negativ beeinträchtigt (Kubler 
and Riezman 1993), stellten wir die Hypothese auf, dass der Defekt der Endozytose einer 
der Hauptstoffwechselmechanismen sein könnte, der die Beeinträchtigungen bei der 
Neurotransmission und an der neuromuskulären Endplatte bei SMA erklärt. Tatsächlich 
stellten wir fest, dass SMN Defizite zu einer verringerten Endozytose in murinen 
embryonalen Fibroblasten führen, während die PLS3-Überexpression wieder zu einer 
Normalisierung des Endozytose führte. 
Zusammenfassend zeigen unsere Erkenntnisse in der transgenen SMA Maus auf, dass eine 
kombinierte Behandlung mit SMN-ASO zusätzlich zur PLS3 Überexpression effizienter 
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wirkt, als eine alleinige Erhöhung der SMN Menge. Folglich weist dies darauf hin, dass 
Substanzen, welche die Endozytose verbessern können, in Kombination mit SMN-ASO 
Therapie nicht nur den SMA Phänotyp verbessern, sondern vielleicht sogar zu einer 
vollständigen Heilung der Krankheit führen könnten. Diese Hypothese stellt eine Grundlage 
für zukünftige Studien dar. 
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